

## PHARMACY / MEDICAL POLICY – 8.01.503

## Immune Globulin Therapy

BCBSA Ref. Policy: 8.01.05

Effective Date: Dec. 5, 2024

Last Revised: Nov. 12, 2024

Replaces: N/A


RELATED MEDICAL POLICIES:

5.01.550 Pharmacotherapy of Arthropathies

11.01.523 Site of Service: Infusion Drugs and Biologic Agents

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)  
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

## Introduction

Immune globulins are proteins made by special cells that help the body fight infections. The proteins are in the blood stream, and are concentrated in plasma, the fluid that is left after removing red and white blood cells from whole blood. Advances in medical technology have made it possible to collect, store and infuse these proteins into other people who have immune system problems. This process is called immune globulin therapy. Some people lack some or all of the cells that make immune globulins. Providing them with intravenous immune globulin therapy can be lifesaving. Other conditions also may improve with immune globulin therapy. This policy describes when the health plan covers the use of immune globulin therapy. For some diseases, the use of immune globulins is still under study. Generally, the use of immune globulin (IVIG) treatment requires pre-approval of the health plan.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs providers about when a service may be covered.

## Policy Coverage Criteria

We will review specific intravenous (IV) and injectable drugs for medical necessity for all ages.

For those age 13 and older, we also will review the site of service for medical necessity. Site of service is defined as the location where the drug is administered, such as a hospital-based outpatient setting, an infusion center, a physician’s office, or at home.

**Drugs subject to site of service review addressed in this policy are:**

- Alyglo
- Asceniv
- Bivigam
- Cutaquig
- Cuvitru
- Flebogamma DIF
- Gammagard
- Gammaked
- Gammaplex
- Gamunex-C
- Hizentra
- Hyqvia
- Octagam
- Panzyga
- Privigen
- Xembify

---

**Click on the links below to be directed to the related medical necessity criteria:**

[Alloimmune Processes](#)

[Miscellaneous](#)

[Autoimmune / Inflammatory Conditions](#)

[Primary Immunodeficiency States](#)

[Hematopoietic Cell Transplantation](#)

[Prior to solid organ transplant](#)

[Infections](#)

[Site of Service](#)

---

<b>Site of Service Administration</b>	<b>Medical Necessity</b>
<b>Medically necessary sites of service</b> <ul style="list-style-type: none"><li>• <b>Physician’s office</b></li><li>• <b>Infusion center</b></li></ul>	<b>IV infusion therapy of various medical or biologic agents will be covered in the most appropriate, safe, and cost-effective site:</b>



Site of Service Administration	Medical Necessity
<ul style="list-style-type: none"> <li>• Home infusion</li> </ul>	<ul style="list-style-type: none"> <li>• These are the preferred <b>medically necessary</b> sites of service for specified drugs.</li> </ul>
<p><b>Hospital-based outpatient setting</b></p> <ul style="list-style-type: none"> <li>• Outpatient hospital IV infusion department</li> <li>• Hospital-based outpatient clinical level of care</li> </ul>	<p><b>IV infusion therapy of various medical or biologic agents will be covered in the most appropriate, safe, and cost-effective site.</b></p> <p><b>This site is considered medically necessary for the first 90 days for the following:</b></p> <ul style="list-style-type: none"> <li>• The initial course of infusion of a pharmacologic or biologic agent</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• Re-initiation of an agent after 6 months or longer following discontinuation of therapy*</li> </ul> <p><b>Note:</b> This does not include when standard dosing between infusions is 6 months or longer</p> <p><b>This site is considered medically necessary when there is no outpatient infusion center within 50 miles of the individual’s home and there is no contracted home infusion agency that will travel to their home, or a hospital is the only place that offers infusions of this drug.</b></p> <p><b>This site is considered medically necessary only when the individual has a clinical condition which puts him or her at increased risk of complications for infusions, including any ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Known cardiac condition (e.g., symptomatic cardiac arrhythmia) or pulmonary condition (e.g., significant respiratory disease, serious obstructive airway disease, %FVC ≤ 40%) that may increase the risk of an adverse reaction</li> <li>• Unstable renal function which decreases the ability to respond to fluids</li> <li>• Difficult or unstable vascular access</li> <li>• Acute mental status changes or cognitive conditions that impact the safety of infusion therapy</li> <li>• A known history of severe adverse drug reactions and/or anaphylaxis to prior treatment with a related or similar drug</li> </ul>



Site of Service Administration	Medical Necessity
<b>Hospital-based outpatient setting</b> <ul style="list-style-type: none"> <li>Outpatient hospital IV infusion department</li> <li>Hospital-based outpatient clinical level of care</li> </ul>	<b>These sites are considered not medically necessary for infusion and injectable therapy services of various medical and biologic agents when the site-of-service criteria in this policy are not met</b>

## Intravenous Immune Globulin (IVIG) Therapy

Condition	Medical Necessity
<b>IVIG therapy is subject to review for site of service administration.</b>	
<b>Immunodeficiency States</b>	
<b>Humoral immunodeficiency states</b>	<b>IVIG therapy may be considered medically necessary for therapeutic use in humoral immunodeficiency states such as acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), lymphoma, or multiple myeloma on anti-B cell immunotherapy (e.g., rituximab, CAR-T, or hematopoietic stem cell transplant [HCT]) when:</b> <ul style="list-style-type: none"> <li>IgG level is less than 500 mg/dl</li> </ul>
<b>Primary immunodeficiency states:</b> <ul style="list-style-type: none"> <li>Ataxia telangiectasia</li> <li>Common variable immunodeficiency</li> <li>Congenital agammaglobulinemia</li> <li>Hypogammaglobulinemia</li> <li>Severe combined immunodeficiency</li> <li>Wiskott-Aldrich syndrome</li> <li>X-linked agammaglobulinemia</li> <li>X-linked hyperimmunoglobulinemia M syndrome</li> </ul>	<b>IVIG therapy may be considered medically necessary when items 1, 2, and 3 are present:</b> <ul style="list-style-type: none"> <li>Laboratory evidence of immunoglobulin deficiency indicated by: <ul style="list-style-type: none"> <li>Agammaglobulinemia (total immunoglobulin G [IgG] less than 200 mg/dl)</li> </ul> </li> <li><b>OR</b> <ul style="list-style-type: none"> <li>Persistent hypogammaglobulinemia (total IgG less than 500 mg/dL, or at least 2 standard deviations below normal, on at least 2 occasions)</li> </ul> </li> <li><b>OR</b> <ul style="list-style-type: none"> <li>Absence of B lymphocytes</li> </ul> </li> <li><b>AND</b> <ul style="list-style-type: none"> <li>Documented inability to mount an adequate immunologic response to inciting antigens as indicated by:</li> </ul> </li> </ul>



Condition	Medical Necessity
<b>IVIG therapy is subject to review for site of service administration.</b>	
	<ul style="list-style-type: none"> <li>○ Lack of appropriate rise in antibody titer following provocation with a polysaccharide antigen</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>○ Lack of appropriate rise in antibody titer following provocation with a protein antigen</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>● Persistent and severe infections, despite treatment with prophylactic antibiotics</li> </ul>
<b>Specific antibody deficiency (SAD)</b>	<p><b>IVIG therapy may be considered medically necessary when ALL the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>● Immunological evaluation with documented normal serum IgG, IgG subclass, IgA, and IgM</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>● Normal responses to protein antigens (e.g. tetanus and diphtheria toxoid) measured 4 weeks after immunization</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>● Inadequate responsiveness to pneumococcal polysaccharide vaccine (e.g., Pneumovax23) 4-8 weeks after vaccination as demonstrated by either of the following: <ul style="list-style-type: none"> <li>○ The individual is aged less than 6 years, less than 50% of serotypes are protective (i.e., equal to or greater than 1.3 mcg/ml per serotype),</li> </ul> </li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>○ The individual is aged 6 years and older, less than 70% of serotypes are protective (i.e., equal to or greater than 1.3 mcg/ml per serotype)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>● Recurrent infections as demonstrated by the following: <ul style="list-style-type: none"> <li>○ History of recurrent, severe bacterial sinopulmonary infections despite treatment with: <ul style="list-style-type: none"> <li>▪ Pneumococcal vaccination,</li> </ul> </li> </ul> </li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>▪ Failure or inadequate response to prophylactic antibiotic therapy</li> </ul>



Condition	Medical Necessity
<b>IVIG therapy is subject to review for site of service administration.</b>	
	<p><b>AND</b></p> <ul style="list-style-type: none"> <li>○ Documented management of underlying asthma or allergic rhinitis (e.g., treatment with nasal or inhaled glucocorticoids, bronchodilators, or antihistamines)</li> </ul>
<b>Infections</b>	
<b>Children with HIV to prevent opportunistic infections</b>	<b>IVIG therapy may be considered medically necessary when the IgG level is less than 500 mg/dl.</b>
<b>Severe anemia associated with human parvovirus B19</b>	<b>IVIG therapy may be considered medically necessary with this documented diagnosis.</b>
<b>Toxic shock syndrome (TSS)</b>	<b>IVIG therapy may be considered medically necessary with this documented diagnosis.</b>
<b>Autoimmune and Inflammatory Conditions</b>	
<p><b>Autoimmune mucocutaneous blistering diseases:</b></p> <ul style="list-style-type: none"> <li>• <b>Pemphigoid:</b> <ul style="list-style-type: none"> <li>○ Bullous pemphigoid</li> <li>○ Mucous membrane pemphigoid</li> </ul> </li> <li>• <b>Pemphigus:</b> <ul style="list-style-type: none"> <li>○ Pemphigus vulgaris</li> <li>○ Pemphigus foliaceus</li> <li>○ Immunoglobulin A (IgA) pemphigus</li> <li>○ Paraneoplastic pemphigus</li> </ul> </li> </ul>	<p><b>IVIG therapy may be considered medically necessary for severe progressive disease, and the individual has failed treatment with conventional agents such as corticosteroids, and immunosuppressive agents (e.g., azathioprine, cyclophosphamide, mycophenolate)</b></p>
<p><b>Immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) (ITP)- <u>Adults</u></b></p>	<p><b>IVIG therapy may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>• Platelet count is <math>&lt;10,000/\text{mm}^3</math> and individual is considered at risk for severe bleeding or intracranial bleeding</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• Platelet count is <math>&lt;30,000/\text{mm}^3</math> and <b>ONE</b> of the following medically necessary situations is present: <ul style="list-style-type: none"> <li>○ Need to rapidly increase platelets due to bleeding, major surgery planned, or risk of intracranial bleeding</li> </ul> </li> </ul> <p><b>OR</b></p>



Condition	Medical Necessity
<b>IVIG therapy is subject to review for site of service administration.</b>	
	<ul style="list-style-type: none"> <li>○ Not a candidate for splenectomy, or experienced relapse post splenectomy</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>○ Failure, contraindication, or intolerance to corticosteroids*</li> </ul> <p><b>Note:</b> See <a href="#">5.01.566- Pharmacotherapy of Thrombocytopenia</a> for more details</p>
<p><b>Immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) (ITP)- <u>Pediatric</u></b></p>	<p><b>IVIG therapy may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>• Platelet count is &lt;30,000/mm<sup>3</sup> and <b>ONE</b> of the following medically necessary situations is present: <ul style="list-style-type: none"> <li>○ Need to rapidly increase platelets due to bleeding, major surgery planned, or risk of intracranial bleeding</li> </ul> </li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>○ Prevention of bleeding in first 12 months after diagnosis</li> </ul>
<p><b>Adults with Guillain-Barré syndrome</b></p>	<p><b>IVIG therapy may be considered medically necessary if the individual is aged 18 years or older and has a confirmed diagnosis of Guillain-Barré syndrome</b></p>
<p><b>Kawasaki syndrome</b></p>	<p><b>IVIG therapy may be considered medically necessary with this documented diagnosis.</b></p>
<p><b>Wegener granulomatosis (GPA)</b></p>	<p><b>IVIG therapy may be considered medically necessary with this documented diagnosis.</b></p>
<p><b>Chronic inflammatory demyelinating polyneuropathy (CIDP) with progressive symptoms for at least 2 months</b></p>	<p><b>IVIG therapy may be considered medically necessary with diagnosis based on:</b></p> <ul style="list-style-type: none"> <li>• Progressive or relapsing motor and/or sensory symptoms of more than one limb <b>AND</b> hyporeflexia or areflexia in affected limbs is present for at least 2 months</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Electrophysiologic findings indicate demyelinating neuropathy (3 of the following 4 criteria are met per the American Academy of Neurology): <ul style="list-style-type: none"> <li>○ Partial conduction block of ≥ 1 motor nerve</li> </ul> </li> </ul>



Condition	Medical Necessity
<b>IVIG therapy is subject to review for site of service administration.</b>	
	<ul style="list-style-type: none"> <li>○ Reduced conduction velocity of <math>\geq 2</math> motor nerves</li> <li>○ Prolonged distal latency of <math>\geq 2</math> motor nerves</li> <li>○ Prolonged F-wave latencies of <math>\geq 2</math> motor nerves or the absence of F waves</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>● Other causes of demyelinating neuropathy have been excluded (Borrelia burgdorferi infection (Lyme disease), diphtheria, drug or toxin exposure, hereditary demyelinating neuropathy, prominent sphincter disturbance, multifocal motor neuropathy (MMN), IgM monoclonal gammopathy, and others</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>● <b>If available</b>, results of other testing to support diagnosis should be provided. Such as: <ul style="list-style-type: none"> <li>○ Cerebrospinal fluid (CSF) examination demonstrating elevated CSF protein with leukocyte count <math>&lt;10/\text{mm}^3</math></li> <li>○ MRI showing gadolinium enhancement and/or hypertrophy of the cauda equina, lumbosacral or cervical nerve roots, or the brachial or lumbosacral plexuses</li> <li>○ Nerve biopsy showing unequivocal evidence of demyelination and/or remyelination by electron microscopy or teased fiber analysis</li> </ul> </li> </ul>
<b>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)</b>	<b>IVIG therapy may be considered medically necessary with this documented diagnosis and the individual fails to respond to one previous therapy (e.g., glucocorticoids or plasma exchange)</b>
<b>Multifocal motor neuropathy</b>	<b>IVIG therapy may be considered medically necessary with this documented diagnosis, and symptoms have been present for one month or longer.</b>
<b>Lambert Eaton myasthenic syndrome</b>	<b>IVIG therapy may be considered medically necessary when the individual fails to respond to amifampridine (i.e., Firdapse), or anticholinesterase medications (e.g., Mestinon, Regonol), or corticosteroids, and/or azathioprine.</b>





Condition	Medical Necessity
<b>IVIG therapy is subject to review for site of service administration.</b>	
<b>Neuromyelitis optica spectrum disorder (previously known as Devic disease or neuromyelitis optica)</b>	<b>IVIG therapy may be considered medically necessary when there is a contraindication to, or lack of response to first-line treatment, such as steroids or plasma exchange.</b>
<b>Severe refractory myasthenia gravis</b>	<b>IVIG therapy may be considered medically necessary when the individual has chronic debilitating disease despite treatment with cholinesterase inhibitors (e.g., Mestinon, Regonol), or complications from or failure of corticosteroids and/or azathioprine.</b>
<b>Myasthenic exacerbation (i.e., acute episode of respiratory muscle weakness)</b>	<b>IVIG therapy may be considered medically necessary when plasma exchange is contraindicated.</b>
<b>Dermatomyositis or polymyositis</b>	<b>IVIG therapy may be considered medically necessary when:</b> <ul style="list-style-type: none"> <li>• Disease is refractory to treatment with corticosteroids <b>AND</b></li> <li>• IVIG is used in combination with other immunosuppressive agents (e.g., azathioprine)</li> </ul>
<b>Warm antibody hemolytic anemia</b>	<b>IVIG therapy may be considered medically necessary when the disease is refractory to other therapies: corticosteroids with/without rituximab, azathioprine, cyclophosphamide, plasmapheresis, or splenectomy.</b>
<b>Antiphospholipid syndrome</b>	<b>IVIG therapy may be considered medically necessary with this documented diagnosis.</b>
<b>Multiple sclerosis</b>	<b>IVIG therapy is considered NOT medically necessary for individuals with any type of multiple sclerosis</b>
<b>Acute antibody-mediated transplant rejection (AMTR)</b>	<b>IVIG therapy may be considered medically necessary with this documented diagnosis.</b>
<b>Alloimmune Processes</b>	
<b>Neonatal alloimmune thrombocytopenia</b>	<b>IVIG therapy may be considered medically necessary with this documented diagnosis.</b>
<b>Hemolytic disease of the fetus and newborn (erythroblastosis fetalis)</b>	<b>IVIG therapy may be considered medically necessary with this documented diagnosis.</b>
<b>Miscellaneous</b>	



Condition	Medical Necessity
<b>IVIG therapy is subject to review for site of service administration.</b>	
<b>Stiff person syndrome</b>	<p><b>IVIG therapy may be considered medically necessary when All of the following are present:</b></p> <ul style="list-style-type: none"> <li>• Diagnosis is based on clinical findings and positive anti-GAD antibodies, or anti-amphiphysin antibodies, and abnormal EMG test</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Activities of daily living are severely limited (e.g., uses walker or cane due to difficulty ambulating)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• The individual has not improved with benzodiazepines (e.g., diazepam) or baclofen</li> </ul>

Condition	Investigational
<b>Impaired immunity states</b>	<p><b>IVIG therapy is considered investigational for the following:</b></p> <ul style="list-style-type: none"> <li>• Prophylactic use post hematopoietic stem cell transplant or in chronic lymphocytic leukemia, lymphoma, multiple myeloma or solid organ transplant</li> <li>• The individuals who have received a solid organ transplant for prophylaxis of acute antibody-mediated transplant rejection</li> <li>• Treatment for individuals at high risk of antibody-mediated transplant rejection including highly sensitized individuals and those receiving an ABO-incompatible organ prior to solid organ transplant</li> </ul>
<b>Infections</b>	<p><b>IVIG therapy is considered investigational for the following:</b></p> <ul style="list-style-type: none"> <li>• The individuals with neonatal sepsis (prophylaxis or treatment)</li> <li>• Adult individuals with sepsis</li> </ul>
<b>Autoimmune and inflammatory conditions</b>	<p><b>IVIG therapy is considered investigational for the following:</b></p> <ul style="list-style-type: none"> <li>• The individuals with Stevens-Johnson syndrome and toxic epidermal necrolysis</li> <li>• With inclusion body myositis</li> <li>• With systemic lupus erythematosus</li> <li>• With immune optic neuritis</li> <li>• With Crohn disease</li> <li>• With hemophagocytic lymphohistiocytosis</li> </ul>
<b>Alloimmune processes</b>	<p><b>IVIG therapy is considered investigational for the following:</b></p> <ul style="list-style-type: none"> <li>• The individuals with recurrent spontaneous abortion</li> </ul>
<b>Miscellaneous</b>	<p><b>IVIG therapy is considered investigational for individuals with:</b></p> <ul style="list-style-type: none"> <li>• Acquired factor VIII inhibitors</li> </ul>



Condition	Investigational
	<ul style="list-style-type: none"> <li>• Acute myocarditis</li> <li>• Adrenoleukodystrophy</li> <li>• Alzheimer disease</li> <li>• Aplastic anemia</li> <li>• Asthma</li> <li>• Autism spectrum disorder</li> <li>• Behçet syndrome</li> <li>• Birdshot retinopathy</li> <li>• Chronic fatigue syndrome</li> <li>• Chronic sinusitis</li> <li>• Complex regional pain syndrome</li> <li>• Cystic fibrosis</li> <li>• Diabetes mellitus</li> <li>• Diamond-Blackfan anemia</li> <li>• Encephalitis</li> <li>• Epidermolysis bullosa acquisita</li> <li>• Epilepsy</li> <li>• Fisher syndrome</li> <li>• Goodpasture syndrome</li> <li>• Hemolytic uremic syndrome</li> <li>• IgG subclass deficiency</li> <li>• Immune-mediated neutropenia</li> <li>• Multiple myeloma</li> <li>• Necrotizing fasciitis</li> <li>• Nonimmune thrombocytopenia</li> <li>• Noninfectious uveitis</li> <li>• Opsoclonus-myoclonus</li> <li>• Organ transplant rejection</li> <li>• Other vasculitides besides Kawasaki disease, including polyarteritis nodosa</li> <li>• Otitis media, recurrent</li> <li>• Paraneoplastic syndromes</li> <li>• Paraproteinemic neuropathy</li> <li>• Pediatric autoimmune neuropsychiatric disorders associated with Streptococcal infections (PANDAS)</li> <li>• Pericarditis, refractory recurrent</li> <li>• Polyradiculoneuropathy (other than chronic inflammatory demyelinating polyneuropathy [CIDP])</li> <li>• Post-polio syndrome</li> <li>• Red cell aplasia</li> <li>• Rheumatoid arthritis, refractory</li> <li>• Thrombotic thrombocytopenic purpura (TTP)</li> </ul>



Condition	Investigational
	<ul style="list-style-type: none"> <li>Vasculitis associated with other connective tissue diseases</li> </ul>

## Subcutaneous Immune Globulin (SCIG) Therapy

Condition	Medical Necessity
Conditions where SCIG is covered	Subcutaneous immune globulin (SCIG) therapy may be considered medically necessary for any condition where IVIG would otherwise be covered.

Condition	Investigational
All other diagnoses	Other applications of SCIG therapy are considered investigational.

Approval	Criteria
Initial authorization	The initial authorization will be for 6 months unless otherwise indicated (e.g., in bone marrow transplant).
Re-authorization	At the time of re-authorization for ongoing care, it is expected that there will be clinical documentation of objective measures of response (e.g., reduction in the incidence of infections) and an IgG $\geq$ 300 mg/dL. Re-authorization will be provided for 12 months unless otherwise indicated.

Documentation Requirements
<p>The medical records submitted for review should document that medical necessity criteria are met. The record should include clinical documentation of:</p> <ul style="list-style-type: none"> <li>Diagnosis/condition</li> <li>History and physical examination documenting the severity of the condition, including frequency and severity of infections if applicable</li> <li>Laboratory results or diagnostic evidence supporting the indication for immune globulin</li> </ul>

## Coding



Code	Description
<b>CPT</b>	
90283	Immune globulin (IgIV), human, for intravenous use
90284	Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each
<b>HCPCS</b>	
J1459	Injection, immune globulin (Privigen), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1551	Injection, immune globulin (Cutaquig), 100 mg
J1554	Injection, immune globulin (asceniv), 500 mg
J1555	Injection, immune globulin (Cuvitru), 100 mg
J1556	Injection, immune globulin (Bivigam), 500 mg
J1557	Injection, immune globulin (Gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1558	Injection, immune globulin (Xembify), 100 mg
J1559	Injection, immune globulin (Hizentra), 100 mg
J1561	Injection, immune globulin (Gamunex/Gamunex-C/Gammaked), non-lyophilized (e.g., liquid), 500 mg
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg (Gammagard SD)
J1568	Injection, immune globulin (Octagam) intravenous, non-lyophilized (e.g., liquid), 500 mg
J1569	Injection, immune globulin (Gammagard liquid) intravenous, non-lyophilized (e.g., liquid), 500 mg
J1572	Injection, immune globulin (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1575	Injection, immune globulin/hyaluronidase, (Hyqvia), 100 mg immune globulin
J1576	Intravenous, non-lyophilized (e.g., liquid), 500 mg (Panzyga)
J1599	Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg (used to report Alyglo)
J3590	Unclassified biologics (used to report Yimmugo)

## Related Information



This policy only addresses nonspecific pooled preparations of immunoglobulin (IG); it does **not** address IG preparations that are specifically used as passive immunization to prevent or reduce infection that may occur with specific viral diseases that include but may not be limited to:

- Cytomegalovirus (CMV)
- Hepatitis A
- Hepatitis B
- Measles
- Respiratory syncytial virus (RSV)
- Rubella
- Varicella/chickenpox

#### **Black Box Warnings and Precautions for IVIG:**

- Thrombosis may occur with immunoglobulin products. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
- For individuals at risk of thrombosis, administer immunoglobulin products at the minimum dose and infusion rate practicable. Ensure adequate hydration in individuals before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in individuals at risk for hyperviscosity.
- Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of human IVIG products in predisposed individuals. Individuals predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes, age greater than 65, volume depletion, sepsis, paraproteinemia, or individuals receiving known nephrotoxic drugs.
- Renal dysfunction and acute renal failure occur more commonly in individuals receiving IVIG products that contain sucrose.



- For individuals at risk of renal dysfunction or renal failure, administer IVIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in individuals before administration.

Additional warnings and precautions include:

- Immunoglobulin A (IgA)-deficient individuals with antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions.
- Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output, in individuals at risk of developing acute renal failure.
- Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in individuals receiving IVIG therapy.
- Thrombosis may occur. Monitor individuals with known risk factors for thrombosis and consider baseline assessment of blood viscosity for those at risk of hyperviscosity
- Aseptic meningitis syndrome may occur in individuals receiving IVIG therapy, especially with high doses or rapid infusion.
- Hemolytic anemia can develop subsequent to IVIG treatment. Monitor individuals for signs and symptoms of hemolysis and hemolytic anemia.
- Monitor individuals for pulmonary adverse reactions (transfusion-related acute lung injury).
- Individuals receiving IVIG for the first time or being restarted on the product after a treatment hiatus of more than 8 weeks may be at a higher risk for developing fever, chills, nausea, and vomiting.
- IVIG is made from human plasma and may contain infectious agents (e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease agent).
- Passive transfer of antibodies may confound serologic testing.

The subcutaneous immunoglobulin (SCIG) product information labels note that reactions similar to other immunoglobulin products may occur. The most common adverse events with subcutaneous injections include local reactions (i.e., swelling, redness, heat, pain, and itching at the injection site).



## Primary Immunodeficiency Syndromes

The diagnosis of immunodeficiency and postimmunization titers must be taken in context with the clinical presentation of the individuals and may vary depending on the type of vaccine given and prior immunization history. The following parameters are examples of criteria for the diagnosis of the primary immunodeficiency syndromes.

- Laboratory evidence of immunoglobulin deficiency may include the following definitions:
  - Agammaglobulinemia (total immunoglobulin G [IgG] < 200 mg/dL)
  - Persistent hypogammaglobulinemia (total IgG < 500 mg/dL, or at least 2 standard deviations below normal, on at least 2 occasions)
  - Absence of B lymphocytes
- Inability to mount an adequate antibody response to inciting antigens may include the following definitions:
  - Lack of appropriate rise in antibody titer following provocation with a polysaccharide antigen.
  - Lack of appropriate rise in antibody titer following provocation with a protein antigen

## Chronic Inflammatory Demyelinating Polyneuropathy

Individuals with chronic inflammatory demyelinating polyneuropathy (CIDP) should have an established diagnosis of CIDP such as criteria established by the American Academy of Neurology in 1991<sup>1</sup> or those described in guidelines from the European Federation of Neurological Societies and the Peripheral Nerve Society, published in 2006 and updated in 2010.<sup>2</sup> There is currently no criterion standard set of clinical or electrophysiologic criteria for the diagnosis of CIDP and its variants.

IVIG treatment in CIDP should be limited to individuals who do not respond to initial therapy with prednisone and are experiencing serious clinical worsening. In individuals treated for chronic diseases (e.g., CIDP, multifocal motor neuropathy, dermatomyositis), the effect of IVIG is transitory and therefore periodic infusions of IVIG are needed to maintain the treatment effect. The frequency of transfusions is titrated to the treatment response; typically, biweekly, or monthly infusions are needed.





## Consideration of Age

In relation to infusion place of service, the age described in this policy for medical necessity of select intravenous and injectable therapy services is 13 years of age or older. The age criteria are based on the following: Pediatric individuals are not small adults. Pediatric individuals differ physiologically, developmentally, cognitively, and emotionally from adult individuals, and vary by age groups from infancy to teen. Children often require smaller doses than adults, lower infusion rates, appropriately sized equipment, the right venipuncture site determined by therapy and age, and behavioral management during administration of care. Specialty infusion training is therefore necessary for pediatric IV insertions and therapy. Due to pediatrics unique physiology and psychology, site of service review is limited to individuals above the age of 13.

The ages stated in this policy for which the drugs are considered medically necessary are based on the US Food and Drug Administration (FDA) labeling for this drug.

## Benefit Application

Based on benefits or contract language, SCIG may be considered either a pharmacy or medical benefit and IVIG is considered a medical benefit.

## Evidence Review

---

### Description

Immunoglobulins are derived from human donor plasma and used to treat an array of disorders, including primary and secondary immune deficiency states and various autoimmune and inflammatory disorders. Human immunoglobulin therapy provides a broad spectrum of opsonizing and neutralizing immunoglobulin G antibodies against a wide variety of bacterial and viral antigens. This policy addresses the use of human immunoglobulin therapy for preventing and/or treating disorders in the inpatient and outpatient settings. Both intravenous immunoglobulin (IVIG) infusion and subcutaneous immunoglobulin (SCIG) infusion are addressed. However, the policy only considers nonspecific pooled preparations of IVIG; it does not consider other preparations used for passive immunization to specific antigens.



## Background

Immunoglobulins are derived from human donor plasma and used to treat an array of disorders, including primary and secondary immunodeficiency states and various autoimmune and inflammatory disorders. Human immunoglobulin therapy provides a broad spectrum of opsonizing and neutralizing immunoglobulin G (IgG) antibodies against a wide variety of bacterial and viral antigens. Two formulations of human IgG are available: intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG). Intramuscular immunoglobulin depot injections have been largely abandoned.

IVIG is an antibody-containing solution obtained from the pooled plasma of healthy blood donors that contains antibodies to greater than 10 million antigens. IVIG has been used to correct immunodeficiencies in individuals with inherited or acquired immunodeficiencies and has also been investigated as an immunomodulator in diseases thought to have an autoimmune basis. Several IVIG products are available for clinical use in the United States. A variety of off-label indications have been investigated; some of the most common are inflammatory myopathies, neuropathies (e.g., Guillain-Barré syndrome), myasthenia gravis, multiple sclerosis, and solid organ transplantation.

This policy only addresses nonspecific pooled preparations of IVIG; it does not address other immunoglobulin preparations specifically used for passive immunization to prevent or attenuate infection with specific viral diseases (e.g., respiratory syncytial virus, cytomegalovirus, hepatitis B).

## Summary of Evidence

### Immunodeficiency States

#### Primary Humoral Immune Deficiencies

Primary humoral immunodeficiency deficiencies refer to diseases resulting from impaired antibody production because of a molecular defect intrinsic to B cells or a failure of interactions between B and T cells. Antibody deficiency characteristically leads to recurrent, often severe upper and lower respiratory tract infections. Findings associated with severe primary humoral immunodeficiencies include failure to thrive, chronic diarrhea, recurrent fever, nodular lymphoid hyperplasia in the gut, and hepatosplenomegaly.

For individuals who have primary humoral immunodeficiency who receive IVIG or SCIG therapy, the evidence includes multiple randomized controlled trials (RCTs) and noncomparative studies.



Relevant outcomes are overall survival, symptoms, change in disease status, morbid events, functional outcomes, hospitalizations, and treatment-related mortality and morbidity. Compared with the standard of care, IVIG and SCIG therapy improved disease-related outcomes. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

### **Hematopoietic Cell Transplantation (Prophylaxis)**

Hematopoietic cell transplantation (HCT) is the intravenous infusion of hematopoietic stem and progenitor cells designed to establish marrow and immune function in individuals with various acquired and inherited malignant and nonmalignant disorders.

For individuals who are undergoing HCT who receive IVIG therapy (prophylaxis), the evidence includes a systematic review, and a meta-analysis. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, quality of life, hospitalizations, and treatment-related mortality and morbidity. Compared with the standard of care, IVIG for routine prophylaxis of infection in individuals undergoing HCT was not associated with survival benefit or reduction in infection. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Acute Antibody-Mediated Rejection After Solid Organ Transplant**

Acute rejection after transplant can be broadly divided into two categories: the more common acute cellular rejection related to activation of T cells, and the less common acute antibody-mediated rejection (ABMR) related to the presence of anti-donor antibodies. Acute ABMR is an entity now better defined and often detected earlier in the clinical course, based on the recognition of characteristic histologic findings, positive C4d staining, and the detection of donor-specific antibodies.

For individuals who are at risk of acute ABMR after solid organ transplants who receive IVIG therapy, the evidence consists of a systematic review, NIH-sponsored RCT, and nonrandomized observational studies. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, quality of life, hospitalizations, and treatment-related mortality and morbidity. The systematic review involving variable quality studies with high to very high risk of bias concluded that there is insufficient data to support or advise against the use of IVIG prophylaxis in solid organ transplants. More adequately powered RCTs are needed. Additionally, studies have shown conflicting results that prophylaxis with IVIG in individuals with high panel



reactive antibody (PRA) levels prior to solid organ transplant leads to a significant reduction in PRA levels. Compared with the standard of care, IVIG for prophylaxis of infection in individuals with high panel reactive antibody levels was not consistently associated with a survival benefit or reduction in infection. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have acute ABMR after solid organ transplants who receive IVIG therapy, the evidence includes retrospective case series and a systematic review. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, quality of life, hospitalizations, and treatment-related mortality and morbidity. Compared with the standard of care, IVIG treatment for ABMR has shown potential benefit in retrospective or small prospective studies; however, larger RCTs with longer follow-up are needed to demonstrate improved health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Chronic Lymphocytic Leukemia**

Chronic lymphocytic leukemia (CLL) is a disorder characterized by progressive accumulation of functionally incompetent lymphocytes; most individuals develop hypogammaglobulinemia at some point in the course of their disease. Individuals experiencing recurrent bacterial infections associated with hypogammaglobulinemia (less than 500 mg/dl) are likely to benefit from monthly infusions of IVIG.

For individuals who have CLL with recurrent bacterial infections associated with hypogammaglobulinemia who receive IVIG therapy, the evidence includes multiple RCTs and a meta-analysis. Relevant outcomes are overall survival, symptoms, morbid events, hospitalizations, and treatment-related mortality and morbidity. Compared with placebo, IVIG treatment for recurrent bacterial infections associated with hypogammaglobulinemia in CLL individuals has shown reductions in minor and moderate infections without a reduction in other clinically important outcomes, including mortality. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.



## Infections

### **HIV-Infected Children**

Prevention of opportunistic infections remains a critical component of care for HIV-infected children even though the availability of combination antiretroviral therapies has substantially and dramatically decreased AIDS-related opportunistic infections and deaths.

For individuals who are HIV-infected children with recurrent bacterial infections associated with hypogammaglobulinemia who receive IVIG therapy, the evidence includes a single RCT. The relevant outcomes are overall survival, symptoms, morbid events, hospitalizations, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy for the prevention of opportunistic infections in HIV-infected children has shown reductions in minor and serious infections without a reduction in other clinically important outcomes, including mortality. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### **Neonatal Sepsis**

Preterm and low birth weight infants are prone to infection because of an immature immune system as well as increased exposure to nosocomial pathogens.

For individuals who are preterm and low birth weight infants with sepsis who receive IVIG therapy (treatment), the evidence includes multiple RCTs and a systematic review. Relevant outcomes are overall survival, symptoms, morbid events, hospitalizations, and treatment-related mortality and morbidity. Compared with placebo, IVIG treatment for neonatal sepsis did not differ significantly in the rates of death or major disability. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### ***Prophylaxis of Neonatal Sepsis***

For individuals who are preterm and low birth weight infants and at risk for sepsis who receive IVIG therapy (prophylaxis), the evidence includes a Cochrane review involving multiple RCTs. Relevant outcomes are overall survival, symptoms, morbid events, hospitalizations, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy for prophylaxis of neonatal sepsis has shown a 3% reduction in sepsis and a 4% reduction in one or more episodes of any serious infection (considered of marginal clinical importance) with no improvement in any of the other clinically important outcomes, including mortality. The



evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Treatment of Sepsis in Adults**

For individuals who are adults with sepsis who receive IVIG therapy, the evidence includes a meta-analysis involving multiple RCTs. Relevant outcomes are overall survival, symptoms, morbid events, hospitalizations, and treatment-related mortality and morbidity. Compared with placebo, IVIG treatment for adult sepsis showed reductions in mortality in the meta-analysis. However, multiple factors preclude recommending the routine use of IVIG to treat sepsis. They include the preponderance of small low-quality studies, the use of heterogeneous dosing regimens, types of IVIG preparations used, and changes over time in the management of sepsis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Severe Anemia Associated with Human Parvovirus B19**

Human parvovirus B19 is a common single-stranded DNA virus. Infections are usually mild or asymptomatic, and do not require treatment. In some cases, the infection can lead to sufficiently severe complications such as transient aplastic crisis, in which case treatment is indicated and may be lifesaving.

For individuals who have severe anemia associated with human parvovirus B19 who receive IVIG therapy, the evidence includes case series. Relevant outcomes are a change in disease status, treatment-related mortality, and treatment-related morbidity. Although observed improvements in outcomes have suggested potential benefits with IVIG therapy, data are retrospective. RCTs are needed to demonstrate improved health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Toxic Shock Syndrome**

Toxic shock syndrome is also called Streptococcal toxic shock syndrome. Streptococcal toxins induce the release of inflammatory cytokines, which cause capillary leakage and tissue damage resulting in shock, multiorgan failure, and death.



For individuals who have toxic shock syndrome who receive IVIG therapy, the evidence includes a small RCT and multiple observational studies. Relevant outcomes are overall survival, change in disease status, morbid events, and treatment-related mortality and morbidity. Compared with placebo, IVIG treatment for toxic shock syndrome in individuals has shown reductions in mortality in a small RCT and in multiple observational studies. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## **Autoimmune and Inflammatory Conditions**

### **Immune thrombocytopenia**

Immune thrombocytopenia (ITP), previously known as idiopathic thrombocytopenic purpura, is an acquired thrombocytopenia caused by autoantibodies against platelet antigens. It is a more common cause of thrombocytopenia in otherwise asymptomatic adults.

For individuals who have ITP who receive IVIG therapy, the evidence includes multiple RCTs, a systematic review, a meta-analysis, and noncomparative studies. Relevant outcomes are disease-specific survival, change in disease status, morbid events, and treatment-related mortality and morbidity. Compared with corticosteroids, IVIG therapy improved platelet counts. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### **Guillain-Barré Syndrome**

Guillain-Barré syndrome (GBS) is a heterogeneous condition with several variant forms and encapsulates many acute immune-mediated polyneuropathies. It is characterized by a rapid onset of muscle weakness caused by the immune system damaging the peripheral nervous system.

For individuals who have Guillain-Barré syndrome who receive IVIG therapy, the evidence includes multiple RCTs, a systematic review, and a meta-analysis. Relevant outcomes are overall survival, disease-specific survival, symptoms, change in disease status, morbid events, and treatment-related mortality and morbidity. Compared with plasma exchange or combination therapy with plasma exchange, IVIG therapy showed similar outcomes. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.



## **Kawasaki Disease**

Kawasaki disease is a very common vasculitis of childhood; it is characterized by fever and manifestations of acute inflammation lasting for an average of 12 days without therapy. It is typically self-limiting but may cause cardiovascular complications, particularly coronary artery aneurysms, which can lead to coronary occlusion and cardiac ischemia ultimately leading to significant morbidity and even death. Therefore, early treatment is essential. Although the mechanism of action of IVIG is not understood, its use early in the course of the disease has reduced the prevalence of coronary artery abnormalities.

For individuals who have Kawasaki disease who receive IVIG therapy, the evidence includes multiple RCTs, a systematic review, and a meta-analysis. Relevant outcomes are disease-specific mortality, change in disease status, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy has shown significant decreases in new coronary artery abnormalities. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## **Granulomatosis with Polyangiitis (Wegener Granulomatosis)**

For individuals who have granulomatosis with polyangiitis (Wegener granulomatosis) who receive IVIG therapy, the evidence includes systematic reviews and an RCT. Relevant outcomes are disease-specific mortality, change in disease status, and treatment-related mortality and morbidity. The success of IVIG in Kawasaki disease has led to the investigation of IVIG therapy for other vasculitides such as Wegener granulomatosis. A 2013 Cochrane review identified 1 RCT on IVIG for Wegener granulomatosis. This small trial found significantly more responders in the IVIG treatment group at 3 months—but no significant differences after 3 months, or in the frequency of relapse or use of other medications. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## **Chronic Inflammatory Demyelinating Polyneuropathy**

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurologic disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder is caused by damage to the myelin sheath of the peripheral nerves. CIDP is difficult to diagnose due to its heterogeneous presentation (both clinical and electrophysiological).

For individuals who have CIDP who receive IVIG therapy, the evidence includes, a systematic review, and RCTs. Relevant outcomes are symptoms, change in disease status, morbid events,





functional outcomes, quality of life, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy has shown clinically meaningful reductions in disability. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have CIDP who receive SCIG therapy, the evidence includes two RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, quality of life, and treatment-related mortality and morbidity. Only one RCT has directly compared SCIG with IVIG in individuals who had CIDP and conclusions about the relative efficacy of the treatments cannot be drawn due to methodologic limitations (e.g., 45% of individuals withdrew from the trial). The other RCT demonstrated that the use of SCIG for the maintenance of CIDP might be effective, with relatively low adverse events, but this trial also had a number of limitations (e.g., small sample, 30% dropout rate). The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Multifocal Motor Neuropathy**

Multifocal motor neuropathy (MMN) is a rare neuropathy characterized by progressive asymmetric weakness and atrophy without sensory abnormalities, a presentation similar to that of motor neuron disease.

For individuals who have MMN who receive IVIG therapy, the evidence includes multiple RCTs and a meta-analysis. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy has shown clinically meaningful reductions in disability and improvements in muscle strength. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### **Lambert-Eaton Myasthenic Syndrome**

Lambert-Eaton myasthenic syndrome is an autoimmune disease with antibodies directed against the neuromuscular junction. Individuals have muscle weakness of the lower extremities, autonomic dysfunction, and extra-ocular muscle impairment. This is a paraneoplastic syndrome associated most commonly with small-cell lung cancer.

For individuals who have Lambert-Eaton myasthenic syndrome who receive IVIG therapy, the evidence includes an RCT, and multiple observational studies. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, quality of life, and treatment-



related mortality and morbidity. Compared with placebo, IVIG therapy has shown clinically meaningful improvements in outcomes assessing muscle strength and activity. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### **Neuromyelitis Optica Spectrum Disorder**

Neuromyelitis optica spectrum disorder is an inflammatory disorder of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting optic nerves and spinal cord. Previously considered a variant of multiple sclerosis, it is now recognized as a distinct clinical entity.

For individuals who have neuromyelitis optica spectrum disorder who receive IVIG therapy, the evidence includes multiple observational studies. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related mortality and morbidity. Studies have shown that IVIG treatment may benefit individuals who are refractory to first-line treatment with steroids or plasma exchange, particularly children. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### **Severe Refractory Myasthenia Gravis or Myasthenic Exacerbation**

Myasthenia gravis (MG) is a relatively rare autoimmune disorder in which antibodies form against acetylcholine nicotinic postsynaptic receptors at the neuromuscular junction of skeletal muscles resulting in characteristic patterns of progressively reduced muscle strength with repeated use and recovery of muscle strength after a period of rest.

For individuals who have severe refractory myasthenia gravis or myasthenic exacerbation who receive IVIG therapy, the evidence includes multiple RCTs and a systematic review. Relevant outcomes are overall survival, symptoms, change in disease status, quality of life, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy has shown clinically meaningful reductions in disability and improvements in muscle strength. Compared with plasma exchange, IVIG therapy did not show significantly improved outcomes but was better tolerated. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.



## **Relapsing-Remitting Multiple Sclerosis**

Relapsing-remitting multiple sclerosis (RRMS) is an immune-mediated inflammatory disease that attacks and destroys myelinated axons in the central nervous system, resulting in variable degrees of physical disability characterized by symptomatic episodes that occur months or years apart and affect different anatomic locations.

For individuals who have RRMS who receive IVIG therapy, the evidence includes a technology assessment. Relevant outcomes are overall survival, disease-specific survival, symptoms, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. According to technology assessments, IVIG therapy is no longer considered a treatment of choice for RRMS. The evidence is insufficient to determine the effects of the technology on health outcomes.

## **Autoimmune Mucocutaneous Blistering Diseases**

Autoimmune mucocutaneous blistering diseases are a group of conditions that manifest with blisters on the skin or mucous membranes and include pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid, cicatricial pemphigoid, dermatitis herpetiformis, and linear IgA dermatosis.

For individuals who have autoimmune mucocutaneous blistering diseases who receive IVIG therapy, the evidence includes two RCTs and a systematic review. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related mortality and morbidity. A systematic review found improvements in over 90% of individuals. RCTs have reported benefits in disease activity in the population as a whole (one trial) or in a subgroup of individuals with severe disease (one trial). The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## **Toxic Epidermal Necrosis and Stevens-Johnson Syndrome**

For individuals who have Toxic Epidermal Necrosis (TEN) or Stevens-Johnson Syndrome (SJS) who receive IVIG therapy, the evidence includes systematic reviews of observational studies. The relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, quality of life, and treatment-related mortality and morbidity. No RCTs have evaluated IVIG for TEN or SJS; most trials that have, have been uncontrolled. A 2016 pooled analysis of data from 11 studies did not find a statistically significant benefit of IVIG therapy for mortality. Compared with placebo, IVIG therapy has not shown statistically significant benefits for



mortality. The evidence is insufficient to determine the effects of the technology on health outcomes.

### ***Idiopathic Inflammatory Myopathies: Dermatomyositis and Polymyositis, Inclusion Body Myositis***

Idiopathic inflammatory myopathies are a group of disorders characterized by inflammation of skeletal muscles and include dermatomyositis, polymyositis and inclusion body myositis. Polymyositis and dermatomyositis involve weakness of the proximal muscles such as the muscles of the hips and thighs, upper arms, and neck. Dermatomyositis is associated with various characteristic skin manifestations. In inclusion body myositis, the muscles most affected are those of the wrists and fingers and the front of the thigh.

#### ***Dermatomyositis and Polymyositis***

For individuals who have dermatomyositis or polymyositis who receive IVIG therapy, the evidence includes a systematic review and RCTs. The relevant outcomes are change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. In one of the RCTs, compared with placebo, IVIG therapy showed significant improvements in muscle strength. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

#### ***Inclusion Body Myositis***

For individuals who have inclusion body myositis who receive IVIG therapy, the evidence includes multiple RCTs. The relevant outcomes are change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy failed to show improvements in muscle strength. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Systemic Lupus Erythematosus**

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease and follows a relapsing and remitting course. It is characterized by an autoantibody response to nuclear and



cytoplasmic antigens. SLE can affect any organ system, but it mainly attacks the skin, joints, kidneys, blood cells, and nervous system.

For individuals who have SLE who receive IVIG therapy, the evidence includes a systematic review of multiple studies. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Although observed improvements in outcomes have suggested potential benefit with IVIG therapy for surrogate outcomes, data are mainly retrospective. More RCTs are needed to demonstrate improved health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Immune Optic Neuritis**

Optic neuritis is an inflammatory demyelinating condition that causes acute, usually monocular, visual loss. It is associated with multiple sclerosis, occurring in 50% of individuals with MS at some time during the course of their illness.

For individuals who have immune optic neuritis who receive IVIG therapy, the evidence includes two RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy has failed to show improvements in vision-related outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Crohn Disease**

Crohn disease is an inflammatory condition of unknown etiology that can affect any portion of the gastrointestinal tract, from the mouth to the perianal area, with a wide spectrum of clinical presentations.

For individuals who have Crohn disease who receive IVIG therapy, the evidence includes multiple case reports of single individuals summarized in a systematic review. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, treatment-related mortality and treatment-related morbidity. The evidence is insufficient to determine the effects of the technology on health outcomes.



## **Hemophagocytic Lymphohistiocytosis**

Hemophagocytic lymphohistiocytosis is an uncommon but potentially fatal syndrome of excessive immune activation resulting from overactive histiocytes and lymphocytes. It may be inherited or acquired.

For individuals who have hemophagocytic lymphohistiocytosis who receive IVIG therapy, the evidence includes multiple case reports summarized in a systematic review and case series. Relevant outcomes are overall survival, disease-specific survival, change in disease status, quality of life, and treatment-related mortality and morbidity. The evidence is insufficient to determine the effects of the technology on health outcomes.

## **Warm Antibody Autoimmune Hemolytic Anemia**

Also known as autoimmune hemolytic anemia, warm antibody autoimmune hemolytic anemia occurs commonly due to IgG antibodies that react with protein antigens on the red blood cell surface at body temperature.

For individuals who have warm antibody autoimmune hemolytic anemia, refractory to prednisone and splenectomy, who receive IVIG therapy, the evidence includes pooled observational data and a case report. Relevant outcomes are a change in disease status, quality of life, and treatment-related mortality and morbidity. Observed improvements in outcomes have suggested potential benefits with IVIG therapy in select individuals with refractory autoimmune hemolytic anemia. RCTs are needed to demonstrate improved health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

## **Antiphospholipid Syndrome**

Antiphospholipid syndrome is an autoimmune disease that results from the development of an antibody against phospholipid proteins, which causes venous or arterial thromboses and/or pregnancy morbidity.

For individuals who have antiphospholipid syndrome who receive IVIG therapy, the evidence includes pooled data from a registry. Relevant outcomes are overall survival, change in disease status, quality of life, and treatment-related mortality and morbidity. Observed improvements in outcomes have suggested potential mortality benefit with IVIG therapy in catastrophic antiphospholipid syndrome. RCTs are needed to demonstrate improved health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.



## Alloimmune Processes

### Neonatal Alloimmune Thrombocytopenia

Fetal and neonatal thrombocytopenia occurs when a maternal antibody directed against a paternal platelet-antigen crosses the placenta and causes thrombocytopenia in the fetus. Intracranial hemorrhage (ICH) occurs in 10% to 30% of affected neonates. Currently, screening for this condition is unavailable and, thus, thrombocytopenia is only identified at birth. However, subsequent fetuses that are platelet-antigen positive also will be at risk for thrombocytopenia and the severity of thrombocytopenia may be increased. Treatment has focused on neonatal platelet transfusions, corticosteroids, and IVIG.

For individuals who have neonatal alloimmune thrombocytopenia who receive IVIG therapy, the evidence includes multiple RCTs and a systematic review. Relevant outcomes are disease-specific survival, change in disease status, and treatment-related mortality and morbidity. Compared with combination use with corticosteroids, IVIG alone did not show any additional increases in platelet counts. Multiple trials have demonstrated increased platelet counts with IVIG therapy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### Recurrent Spontaneous Abortion

Recurrent spontaneous abortion (RSA) is defined as 3 or more pregnancies resulting in a spontaneous abortion before 16 to 20 weeks of gestational age. Women with recurrent spontaneous abortion frequently have immunologic abnormalities, particularly antiphospholipid antibodies whose incidence may increase with each subsequent pregnancy loss.

For individuals who have a recurrent spontaneous abortion who receive IVIG therapy, the evidence includes multiple RCTs and a systematic review. Relevant outcomes are disease-specific survival, treatment-related mortality, and treatment-related morbidity. In multiple RCTs, compared with placebo, IVIG therapy alone did not show any beneficial effects in preventing spontaneous abortions. The evidence is insufficient to determine the effects of the technology on health outcomes.



## Miscellaneous Indications

### **Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections**

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is a term used to describe a subset of children whose symptoms of obsessive-compulsive disorder (or tic disorders) are exacerbated by group A streptococcal infections. This syndrome is not well-understood, and the diagnosis of PANDAS requires expert consultation.

For individuals who have PANDAS who receive IVIG therapy, the evidence includes two small RCTs. Relevant outcomes are symptoms, change in disease status, and treatment-related mortality and morbidity. The trials had mixed findings and both had small sample sizes and short intervention duration. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Autism Spectrum Disorder**

Autism spectrum disorder is a neurodevelopmental disorder characterized by deficits in social communication and interaction and restricted repetitive patterns of behavior, interests, and activities.

For individuals who have autism spectrum disorder who receive IVIG therapy, the evidence includes case series. Relevant outcomes are symptoms, change in disease status, functional outcomes, health status measures, quality of life, treatment-related mortality and treatment-related morbidity. Although improvements were observed in one case series, the other two reported negative findings. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Complex Regional Pain Syndrome**

Complex regional pain syndrome (CRPS) is defined as a disorder of the extremities characterized by regional pain that is disproportionate in time or degree to the usual course of any known trauma or other lesions.

For individuals who have CRPS who receive IVIG therapy, the evidence includes two RCTs. Relevant outcomes are symptoms, morbid events, quality of life, and treatment-related mortality and morbidity. In one trial, compared with placebo, IVIG therapy was associated with





improvements in pain scores. However, methodologic limitations restrict the conclusions drawn from data on 13 individuals. In the other RCT, low-dose IVIG was ineffective in relieving pain in CRPS. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Alzheimer Disease**

For individuals who have Alzheimer disease who receive IVIG therapy, the evidence includes three RCTs. Relevant outcomes are overall survival, disease-specific survival, symptoms, change in disease status, quality of life, and treatment-related mortality and morbidity. With the exception of a few subgroup analyses using mild cognitive impairment status, IVIG therapy was not significantly better than a placebo for outcomes such as brain atrophy, level of plasma amyloid  $\beta$  1–40, or cognition and function. Studies differed by treatment protocols, outcomes assessed, and two of the three had relatively small sample sizes. Additional RCTs could be conducted to confirm whether IVIG benefits individuals with early mild cognitive impairment. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Paraproteinemic Neuropathy**

Paraproteinemic neuropathy is a heterogeneous set of neuropathies characterized by the presence of paraproteins, which are immunoglobulins produced in excess by an abnormal clonal proliferation of B lymphocytes or plasma cells. Paraproteinemic neuropathy may be caused by the interaction of antibodies with specific antigenic targets on peripheral nerves or by deposition of immunoglobulins or amyloid.

For individuals who have paraproteinemic neuropathy who receive IVIG therapy, the evidence includes two small RCTs. Relevant outcomes are a change in disease status, quality of life, and treatment-related mortality and morbidity. Compared with placebo, IVIG showed mild and transitory improvements in one trial but failed to show any improvement in another. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Chronic Fatigue Syndrome**

Chronic fatigue syndrome (aka systemic exertion intolerance disease) is a complex and controversial disease with multiple definitions.



For individuals who have chronic fatigue syndrome who receive IVIG therapy, the evidence includes an RCT and anecdotal reports. Relevant outcomes are symptoms, quality of life, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy has shown no therapeutic benefits. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Acute Myocarditis**

Acute myocarditis is a sudden inflammation of the myocardium that can occur in individuals of all ages. It is presumed to start as a viral infection, although autoimmune and idiopathic forms also occur. It remains unclear whether the primary problem is most commonly ongoing damage from a virus, a post-infectious inflammatory reaction, or a combination of the two.

For individuals who have acute myocarditis who receive IVIG therapy, the evidence includes a meta-analysis, RCTs and a retrospective study. Results from a Cochrane review concluded that, after pooling the available data, there was uncertain evidence of the effect of IVIG in preventing deaths. More RCT evidence is required before IVIG can be routinely recommended in the setting of myocarditis. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Refractory Recurrent Pericarditis**

Refractory recurrent pericarditis is defined as recurrent pericarditis not responding to conventional anti-inflammatories such as aspirin, nonsteroidal inflammatory drugs, corticosteroids, and colchicine.

For individuals who have refractory recurrent pericarditis who receive IVIG therapy, the evidence includes a systematic review of multiple case reports and case series. The relevant outcomes are overall survival, change in disease status, quality of life, and treatment-related mortality and morbidity. Although improvements were observed in some individuals, controlled trials are lacking. The evidence is insufficient to determine the effects of the technology on health outcomes.



## **Stiff Person Syndrome**

Stiff person syndrome is a rare acquired neurologic disorder characterized by progressive muscle stiffness, rigidity, and spasm involving the axial muscles, resulting in severely impaired ambulation. It is caused by increased muscle activity due to decreased inhibition of the central nervous system. If left untreated, stiff person syndrome can progress to cause difficulty walking and significantly impact a person's ability to perform routine, daily tasks.

For individuals who have stiff-person syndrome who receive IVIG therapy, the evidence includes a small, randomized crossover study. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Compared with placebo, IVIG therapy has shown decreases in stiffness scores and improvements in functional outcomes. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

## **Noninfectious Uveitis**

Noninfectious uveitis is inflammation of the eye that results from eye trauma, anomalous immune processes, or unknown etiology.

For individuals who have noninfectious uveitis who receive IVIG therapy, the evidence includes two small case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related mortality and morbidity. The case series reported measurable improvements in visual acuity after IVIG therapy, but controlled studies are needed to draw conclusions about the efficacy of IVIG for this population. The evidence is insufficient to determine the effects of the technology on health outcomes.

## **Post-Polio Syndrome**

Although polio no longer poses a major public health threat in the United States, many individuals live with the sequelae of paralytic polio. Many polio survivors experience a modest decline in function and muscle strength over many years that may reflect the natural history of polio.

For individuals who have post-polio syndrome who receive IVIG therapy, the evidence includes a systematic review of multiple RCTs and nonrandomized prospective studies. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related mortality and



morbidity. Compared with placebo, IVIG therapy has failed to show reductions in the severity of pain and fatigue or improvements in muscle strength. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Necrotizing Fasciitis**

For individuals who have necrotizing fasciitis who receive IVIG therapy, the evidence includes an RCT. The relevant outcomes are overall survival, symptoms, functional outcomes, and treatment-related mortality and morbidity. The RCT found that, compared with placebo, IVIG therapy did not significantly improve functional outcomes, mortality rates, or other outcomes (e.g., the use of life support in the intensive care unit). Additional controlled studies are needed to draw conclusions about the efficacy of IVIG for treating necrotizing fasciitis. The evidence is insufficient to determine the effects of the technology on health outcomes.

## **Clinical Input from Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received through 3 physician specialty societies and 5 academic medical centers in March 2013 after this policy was under review in 2012. Input focused on intravenous immunoglobulin (IVIG) treatment for seven rare conditions. There was consensus, or near-consensus, that IVIG is investigational for six of these conditions: birdshot retinopathy, epidermolysis bullosa acquisita, necrotizing fasciitis, opsoclonus myoclonus, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, and polyradiculoneuropathy (other than chronic inflammatory demyelinating polyneuropathy). Clinical input was mixed overall on the seventh condition, IVIG for treating severe anemia associated with parvovirus B19.

Additional clinical input was obtained in June 2013, focusing on severe anemia due to parvovirus B19. Input was received from 3 reviewers (all hematologists), and there was consensus that IVIG is not investigational for this indication. There was a lack of consensus among the three reviewers on any specific clinical or individual characteristics that can be used to select



individuals with severe anemia due to parvovirus B19 for treatment with IVIG and on any treatments that should be used by these individuals before IVIG.

## Practice Guidelines and Position Statements

### American Academy of Allergy, Asthma, and Immunology Work Group Report

In 2017, the American Academy of Allergy, Asthma, and Immunology (AAAAI) published an updated Work Group Report on the use of immunoglobulin in human disease that evaluated published data through June 2015.<sup>138</sup> Table 1 summarizes the conclusions of the Work Group regarding the potential benefit of immune globulin therapy for various disease states.

**Table 1. AAAAI Work Group Report Immune Globulin Recommendations<sup>138</sup>**

Benefit of Immune Globulin Therapy	Disease State
Definitely beneficial	<ul style="list-style-type: none"> <li>• Primary immune defects with absent B cells</li> <li>• Primary immune defects with hypogammaglobulinemia and impaired specific antibody production</li> <li>• Distinct genetically defined primary immunodeficiencies with variable defects in antibody quality and quantity</li> <li>• Graves ophthalmopathy</li> <li>• ITP</li> <li>• Kawasaki disease</li> <li>• Reduction of secondary infections in pediatric HIV infection</li> <li>• CMV pneumonitis in solid organ transplants</li> <li>• CIDP</li> <li>• Multifocal motor neuropathy</li> <li>• Guillain-Barré syndrome</li> </ul>
Probably beneficial	<ul style="list-style-type: none"> <li>• Chronic lymphocytic leukemia with reduced IgG and history of infections</li> <li>• Prevention of bacterial infection in HIV-infected children</li> <li>• Primary immune defects with normal IgG and impaired specific antibody production</li> <li>• Dermatomyositis</li> <li>• Birdshot retinopathy</li> </ul>



Benefit of Immune Globulin Therapy	Disease State
	<ul style="list-style-type: none"> <li>• Henoch-Schonlein purpura</li> <li>• Neonatal sepsis</li> <li>• Rotaviral enterocolitis</li> <li>• Bacterial infections in lymphoproliferative disease</li> <li>• Toxic shock syndrome</li> <li>• Enteroviral meningoencephalitis</li> <li>• IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy</li> <li>• Lambert-Eaton myasthenia syndrome</li> <li>• Myasthenia gravis</li> <li>• Stiff-person syndrome</li> <li>• Toxic epidermal necrolysis and Stevens-Johnson syndrome</li> </ul>
May provide benefit	<ul style="list-style-type: none"> <li>• Rasmussen syndrome</li> <li>• Acute disseminated encephalomyelitis</li> <li>• Human T-lymphotropic virus I-associated myelopathy</li> <li>• Cerebral infarctions with anti-phospholipid antibodies</li> <li>• Demyelinative brain stem encephalitis</li> <li>• Lumbosacral or brachial plexitis</li> <li>• Paraproteinemic neuropathy</li> <li>• Autoimmune encephalitides</li> <li>• Opsoclonus myoclonus syndrome</li> <li>• Postinfectious cerebellar ataxia</li> <li>• Acute idiopathic dysautonomia</li> <li>• Autoimmune optic neuropathy</li> <li>• Paraneoplastic cerebellar degeneration</li> <li>• Brown-Vialetto-Van Laere syndrome</li> <li>• Alzheimer disease</li> <li>• Narcolepsy with cataplexy</li> <li>• Limbic encephalitis</li> <li>• Prevention of infection and acute GVHD post-BMT</li> <li>• Prevention of acute humoral rejection in renal transplantation</li> <li>• PANDAS</li> <li>• Delayed pressure urticities</li> <li>• Severe persistent high-dose steroid-dependent asthma</li> <li>• Treatment of acute humoral rejection in renal transplantation</li> <li>• Autoimmune blistering skin diseases and manifestation of systemic diseases</li> <li>• Chronic urticities</li> <li>• Autoimmune liver disease</li> <li>• Acute myocarditis</li> <li>• Atopic dermatitis</li> <li>• Prevention of unexplained spontaneous recurrent abortion</li> </ul>



Benefit of Immune Globulin Therapy	Disease State
	<ul style="list-style-type: none"> <li>• Prevention of neonatal sepsis</li> <li>• Transient hypogammaglobulinemia of infancy</li> <li>• Other immune mechanism driving recurrent infections that affect B-cell function</li> <li>• Selective antibody deficiency “memory phenotype”</li> <li>• Isolated IgG subclass deficiency (IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>) with recurrent infections</li> <li>• Juvenile idiopathic arthritis</li> <li>• Anti-phospholipid antibody syndrome in pregnancy</li> <li>• Severe rheumatoid arthritis</li> <li>• Still disease</li> <li>• Felty syndrome</li> <li>• Macrophage activation syndrome</li> <li>• Polyarteritis nodosa</li> <li>• Post-transfusion purpura</li> <li>• Thrombotic thrombocytopenic purpura</li> <li>• ANCA syndromes</li> <li>• Autoimmune neutropenia</li> <li>• Autoimmune hemolytic anemia/Evan syndrome</li> <li>• Autoimmune hemophilia</li> <li>• Systemic lupus erythematosus</li> <li>• Neonatal alloimmune thrombocytopenia</li> <li>• Neonatal isoimmune hemolytic jaundice</li> <li>• Cystic fibrosis with hypogammaglobulinemia</li> <li>• Postoperative sepsis</li> <li>• Respiratory syncytial virus lower respiratory tract infection (proven for palivizumab)</li> <li>• Pseudomembranous colitis</li> <li>• Campylobacter enteritis</li> <li>• Chronic parvovirus B19</li> <li>• Relapsing-remitting multiple sclerosis</li> <li>• Intractable childhood epilepsy</li> <li>• Postpolio syndrome</li> </ul>
Unlikely to be beneficial	<ul style="list-style-type: none"> <li>• Isolated IgE deficiency</li> <li>• Isolated IgG<sub>4</sub> deficiency</li> <li>• Selective IgA deficiency</li> <li>• Isolated IgM deficiency</li> <li>• Inclusion body myositis</li> <li>• Autoimmune diabetes mellitus</li> <li>• Inflammatory bowel disease</li> <li>• Chronic fatigue syndrome</li> <li>• Cystic fibrosis without hypogammaglobulinemia</li> <li>• Acute rheumatic fever</li> </ul>



Benefit of Immune Globulin Therapy	Disease State
	<ul style="list-style-type: none"> <li>• Viral load in HIV infection</li> <li>• Demyelinating neuropathy associated with monoclonal IgM</li> <li>• Adrenoleukodystrophy</li> <li>• Amyotrophic lateral sclerosis</li> <li>• POEMS syndrome</li> <li>• Paraneoplastic cerebellar degeneration, sensory neuropathy or encephalopathy</li> <li>• Brachial plexopathy</li> <li>• Autism</li> <li>• Non-steroid dependent asthma</li> <li>• Dilated cardiomyopathy</li> </ul>

ANCA=anti-neutrophil cytoplasmic autoantibody; BMT=bone marrow transplant; CIDP=chronic inflammatory demyelinating polyneuropathy; CMV=cytomegalovirus; GVHD=graft versus host disease; HIV=human immunodeficiency virus; IgG=immunoglobulin G; ITP=idiopathic thrombocytopenic purpura; PANDAS= pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections; POEMS=polyneuropathy, organomegaly, endocrinopathy, monoclonal protein.

## Disease State Guidelines

### Immunodeficiency States

#### Primary Humoral Immune Deficiencies

##### ***National Advisory Committee on Blood and Blood Products and Canadian Blood Services***

The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services (CBS) (2010) published guidelines on the use of immunoglobulin therapy for individuals with primary immune deficiency.<sup>4</sup> The guidelines reported that there was sufficient evidence that immunoglobulin therapy reduces the rate of infection and hospitalization in individuals with primary immune deficiency, lowers mortality, and improves quality of life. Treatment should be started at a dose of 400 to 600 mg/kg per 4 weeks for intravenous immunoglobulin (IVIG) or 100 to 150 mg/kg per week for subcutaneous immunoglobulin (SCIG) infusion.





## ***American Academy of Allergy, Asthma, and Immunology***

The American Academy of Allergy, Asthma, and Immunology (2015) published practice parameters for the diagnosis and management of primary immunodeficiency.<sup>139</sup> The Academy advised that treatment of these conditions include antibiotic prophylaxis and immunoglobulin G (IgG) replacement.

## **Hematopoietic Cell Transplantation (Prophylaxis)**

The NAC and CBS (2007) published guidelines on the use of IVIG for hematologic conditions.<sup>40</sup> The guidelines stated that evidence does not support the use of IVIG after hematopoietic cell transplantation.

## **Acute Antibody-Mediated Rejection After Solid Organ Transplant**

The CBS and NAC (2010) developed guidelines addressing the use of IVIG for sensitized individuals undergoing solid organ transplantation.<sup>140</sup> The following conclusions were issued on non-kidney solid organ transplantation:

- For individuals undergoing heart transplantation, to improve graft/overall survival or to treat rejection: insufficient evidence to recommend for or against the routine use of IVIG (however, other factors may influence decision-making)
- For desensitization for individuals undergoing lung transplantation or for the treatment of rejection: insufficient evidence to make a recommendation for or against the routine use of IVIG (however, other factors may influence decision-making)
- For individuals undergoing liver transplantation or for the treatment of rejection/ABO-incompatible liver transplantation: insufficient evidence to make a recommendation for or against the routine use of IVIG
- For the use of IVIG for solid organ transplantation: limited methodologically rigorous evidence
- Future studies are needed to delineate the effect of IVIG on desensitization using standardized methods for desensitization; the effect of IVIG on acute rejection rates, graft survival, and overall survival; the use of the combined modality IVIG and plasmapheresis compared either to plasmapheresis or IVIG alone; and the optimum dosage of IVIG.



## **Chronic Lymphocytic Leukemia**

The National Comprehensive Cancer Network guidelines (v.3.2024) on chronic lymphocytic leukemia recommend IVIG as supportive care for individuals with chronic lymphocytic leukemia: for the treatment of autoimmune cytopenias and recurrent sinopulmonary infections (IgG levels <500 mg/dL).<sup>141</sup> The guidelines recommend monitoring IVIG levels and administering monthly IVIG (0.3 to 0.5 g/kg) to maintain levels of 500 mg/dl.

## **Infections**

### **Infections in HIV-Infected Children**

In 2020, updated joint guidelines on the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children were published. The guidelines, endorsed by the American Academy of Pediatrics, the Infectious Diseases Society of America, and other agencies and societies, included the following statement:

- "Intravenous immune globulin is recommended to prevent serious bacterial infections in HIV-infected children who have hypogammaglobulinemia."
- In rare situations in which cART and antibiotic prophylaxis are not effective in preventing frequent recurrent serious bacterial infections, IVIG prophylaxis can be considered for secondary prophylaxis."

### **Neonatal Sepsis**

The American Academy of Pediatrics (2018) published guidelines on the management of neonates with suspected or proven early-onset bacterial sepsis.<sup>143</sup> The guidelines did not address the use of IVIG to treat neonatal sepsis.



## Autoimmune and Inflammatory Conditions

### Immune Thrombocytopenia

The NAC and CBS (2007) issued guidelines on the use of IVIG for hematologic conditions, including immune thrombocytopenia (ITP).<sup>40</sup> Recommendations for individuals with ITP are as follows:

- Adult acute ITP with bleeding: IVIG is strongly recommended as a part of multimodality therapy for major or life-threatening bleeding complications and/or clinically important mucocutaneous bleeding.
- Adult acute ITP with severe thrombocytopenia but no bleeding: IVIG is not recommended as first-line therapy alone, except for individuals with contraindications to corticosteroids.
- Adult ITP with no or slow response to adequate dose corticosteroids: IVIG may be considered as a possible adjunctive therapy.
- Adult chronic ITP post-splenectomy: IVIG may be considered as a possible adjunctive therapy as a corticosteroid-sparing measure. The minimal dose of IVIG should be used that maintains a safe platelet count. Individuals should be reevaluated every three to six months, and alternative therapies to IVIG should be considered for individuals who do not achieve a durable response for a minimum of two to three weeks.

### Guillain-Barré Syndrome

The American Academy of Neurology (AAN; 2012) guidelines on the treatment of neuromuscular disorders concluded that IVIG is as efficacious as plasmapheresis and should be offered as a treatment option to adults with Guillain-Barré syndrome (Level A).<sup>144</sup> The guidelines indicated that there was insufficient evidence to support or refute the use of IVIG in children.

The European Federation of Neurological Societies (EFNS; 2008) issued guidelines on the use of IVIG for the treatment of neurological disorders.<sup>145</sup> The guidelines stated that the efficacy of IVIG treatment of Guillain-Barré syndrome has been established (level A).

### Kawasaki Syndrome and Other Vasculitides

The American Academy of Family Physicians (2015)<sup>146</sup> and the American Heart Association (2017)<sup>147</sup> have supported the use of IVIG in the treatment of Kawasaki syndrome.



## Chronic Inflammatory Demyelinating Polyneuropathy

The AAN (2012) guidelines on the treatment of neuromuscular disorders stated that IVIG is effective and should be offered as a long-term treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) (level A).<sup>144</sup> The guidelines indicated that data are insufficient to compare the efficacy of prednisone and IVIG in the treatment of CIDP.

The EFNS and the Peripheral Nerve Society published updated guidelines on the management of chronic inflammatory demyelinating polyradiculoneuropathy (CIPD) in 2021.

- "Both IVIG and oral or intravenous corticosteroids are first-line treatments for CIDP. Based on the level of evidence, the task force did not recommend an overall preference for either treatment modality and weakly recommended either IVIG or corticosteroid treatment. "
- "Both short- and long-term effectiveness, risks, ease of implementation, and cost should be considered:
  - IVIG may be preferable when it comes to short-term treatment effectiveness, or when (relative) contraindications for corticosteroids exist.
  - There is some indication that pulsed corticosteroids may be preferable for long-term treatment effectiveness, because of a possible higher rate and longer duration of remission, or when IVIG is unaffordable or unavailable."
- "Although the evidence from studies is limited, the task force weakly recommended treatment with IVIG compared with plasma exchange, mainly based on the ease of administration of IVIG.
  - In some individuals with good vascular access, plasma exchange may be an acceptable option for chronic treatment."
- "The task force strongly recommended using SCIG for maintenance treatment in CIDP."
- "The task force recommended no preference for either IVIG or SCIG for maintenance treatment in CIDP."
- "During follow-up, the dose should be tailored according to individual treatment response."
- "The task force weakly recommended against using SCIG for induction treatment in CIDP."



## **Multifocal Motor Neuropathy**

The AAN (2012) guidelines on the treatment of neuromuscular disorders stated that IVIG is probably effective and should be considered for the treatment of multifocal motor neuropathy (level B).<sup>144</sup> There were insufficient data to determine the optimal treatment interval, dosing, and duration.

## **Lambert-Eaton Myasthenic Syndrome**

The AAN (2012) guidelines on the treatment of neuromuscular disorders stated that IVIG is possibly effective and may be considered for treating Lambert-Eaton myasthenic syndrome (level C).<sup>144</sup>

## **Neuromyelitis Optica Spectrum Disorder**

According to the Neuromyelitis Optica's (2014) updated guidelines, high-dose IVIG is potentially beneficial in the long-term treatment of neuromyelitis optica and may be used as an alternative for individuals with a contraindication to one of the other treatments or, particularly, in children.<sup>148</sup>

## **Severe Refractory Myasthenia Gravis or Myasthenic Exacerbation**

In 2013, the Myasthenia Gravis Foundation of America appointed a task force to develop an international consensus guidance<sup>149</sup> that focused on the appropriate management of myasthenia gravis. The authors of this guidance recommended the use of IGIV or plasma exchange for short-term treatment in individuals with myasthenia gravis with life-threatening signs such as respiratory insufficiency or dysphagia; in preparation for surgery in individuals with significant bulbar dysfunction; when a rapid response to treatment is needed; when other treatments are insufficiently effective; and prior to beginning corticosteroids if deemed necessary to prevent or minimize exacerbations. Additionally, the guidance notes that the choice between plasma exchange and IGIV depends on individual patient factors and availability and that each therapy is probably equally effective in the treatment of severe generalized myasthenia gravis. For milder myasthenia gravis or ocular myasthenia gravis, the efficacy of IGIV is less certain. The use of IGIV as maintenance therapy can be considered for individuals with refractory myasthenia gravis or for those in whom immunosuppressive agents are relatively contraindicated.



The AAN (2012) guidelines on the treatment of neuromuscular disorders concluded that IVIG therapy is probably effective in treating individuals with severe myasthenia gravis and should be considered in the treatment plan (level B).<sup>144</sup> There was insufficient evidence to compare IVIG and plasmapheresis in the treatment of these individuals.

### **Relapsing-Remitting Multiple Sclerosis**

The AAN (2002) published a technology assessment on therapies for multiple sclerosis.<sup>78</sup> The assessment was reviewed and reaffirmed in 2018. The assessment offered the following recommendations on IVIG:

- Studies of IVIG to date have generally involved small numbers of individuals, have lacked complete data on clinical and MRI (magnetic resonance imaging) outcomes, or have used methods that have been questioned. It is, therefore, only possible that IVIG reduces the attack rate in relapsing-remitting multiple sclerosis (type C recommendation: possibly effective, ineffective, or harmful).
- Current evidence suggests that IVIG is of little benefit with regard to slowing disease progression (type C recommendation: possibly effective, ineffective, or harmful).

The EFNS (2008) issued guidelines on the use of IVIG for the treatment of neurologic disorders.<sup>145</sup> The guidelines recommended IVIG as second- or third-line therapy for relapsing-remitting multiple sclerosis if conventional immunomodulatory therapies are not tolerated (level B).

### **Autoimmune Mucocutaneous Blistering Diseases**

In 2003, a consensus statement on the use of immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases was published.<sup>150</sup> The authors of this statement recommended that immune globulin products be administered in the following situations:

- Failure of conventional therapy
- Contraindications to, or significant adverse effects of, standard treatment
- Progressive disease while receiving appropriate therapy
- Uncontrolled rapidly progressive disease



## **Toxic Epidermal Necrosis and Stevens-Johnson Syndrome**

The British Association of Dermatologists (2016) published guidelines on the management of toxic epidermal necrosis and Stevens-Johnson syndrome in adults.<sup>151</sup> These guidelines are accredited by the National Institute for Health and Care Excellence. The guidelines indicated that evidence for the use of IVIG in the treatment of toxic epidermal necrosis and Stevens-Johnson syndrome was not of sufficient quality or consistency.

The British Association of Dermatologists (2019) published guidelines for the management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children and young people, which said, "There is no reliable evidence on the benefits or lack of benefit of any systemic treatments including prednisolone, IVIg, anti-tumor necrosis factor (TNF) biologics or ciclosporin."<sup>152</sup>

## **Idiopathic Inflammatory Myopathies**

The AAN (2012) guidelines on IVIG for treating neuromuscular disorders have stated that IVIG is possibly effective and may be considered as a treatment for nonresponsive dermatomyositis (an idiopathic inflammatory condition) in adults (level C).<sup>144</sup>

## **Immune Optic Neuritis**

Optic neuritis presents as a manifestation of multiple sclerosis (see the [Relapsing-Remitting Multiple Sclerosis](#) section above).

## **Alloimmune Processes**

### **Antiphospholipid syndrome**

In 2014, the Task Force on Catastrophic Antiphospholipid Syndrome concluded that triple therapy involving anticoagulation with heparin, glucocorticoids, plus either plasma exchange, IVIG, or both "has affected mortality compared to other strategies that did not use plasma exchange, IVIG, or both."<sup>153</sup> This is a Grade B recommendation.

### **Neonatal Alloimmune Thrombocytopenia**

The NAC and CBS (2007) published guidelines on the use of IVIG for hematologic conditions.<sup>40</sup>



- Treatment of fetus: Evidence is limited and weak but given that the condition is rare and the consequences are serious, IVIG was deemed an appropriate option and should be considered the standard of care.
- Treatment of newborn: First line therapy should be antigen-negative compatible platelets, with IVIG considered as adjunctive therapy.

### **Recurrent Spontaneous Abortion**

The Royal College of Obstetricians and Gynecologists (2011; reviewed in 2017) issued guidelines on the treatment of recurrent first- and second-trimester miscarriages.<sup>154</sup> The guidelines, accredited by the National Institute for Health and Care Excellence, concluded that IVIG does not improve the live birth rate in women with recurrent miscarriages (level A).

## **Miscellaneous**

### **Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections**

The NAC and CBS (2007) convened a panel of national experts to develop evidence-based practice guidelines on the use of IVIG for neurologic conditions.<sup>155</sup> The panel recommended the use of IVIG for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. The optimal dose and duration of treatment is uncertain.

### **Autism Spectrum Disorder**

The NAC and CBS (2007) guidelines on neurologic conditions did not recommend IVIG for autism.<sup>155</sup>

The American Academy of Child and Adolescent Psychiatry (2014) published practice parameters on the assessment and treatment of autism spectrum disorder.<sup>156</sup> The Academy parameters did not address the use of IVIG for the treatment of autism spectrum disorder.





## **Chronic Fatigue Syndrome**

The National Institute for Health and Care Excellence (2007; currently undergoing an updated development) issued guidance on the diagnosis and management of chronic fatigue syndrome.<sup>157</sup> The guidance indicated that there is no cure for chronic fatigue syndrome and that symptoms (pain, sleep disturbances, physical limitations, and debilitating fatigue) should be managed under the supervision of a specialist. The use of IVIG was not addressed.

## **Viral Myocarditis**

The, the American College of Cardiology Foundation and the American Heart Association issued joint guidelines on the management of heart failure.<sup>158</sup> The guidelines did not address the use of IVIG for the treatment of viral myocarditis.

## **Medicare National Coverage**

The Centers for Medicare & Medicaid Services (2002) published a national coverage determination on IVIG for the treatment of autoimmune mucocutaneous blistering diseases.<sup>160</sup> IVIG is covered for individuals with biopsy-proven disease who have failed conventional therapy or for whom conventional therapy is contraindicated, and to supplement conventional therapy in individuals with rapidly progressive disease.

No national coverage determinations on other uses of IVIG or subcutaneous immune globulin were identified.

## **Ongoing and Unpublished Clinical Trials**

Some currently ongoing and unpublished trials that might influence this policy are listed in [Table 2](#).



**Table 2. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>Ongoing</b>			
NCT02176863 <sup>a</sup>	A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome	210	Sep 2023
NCT03194815	IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 (SINAPPS2)	80	Mar 2024
<b>Unpublished</b>			
NCT03065244	KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)	105	Nov 2020

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## Regulatory Status

Several IVIG products have been approved by the FDA. These products include Asceniv (ADMA Biologics), Bivigam (ADMA Biologics), Flebogamma DIF (Instituto Grifols), Gammagard Liquid (Takeda), Gammagard S/D (Takeda), Gammaked (Kedrion Biopharma), Gammaplex (Bio Products Lab), Gamunex-C (Grifols Therapeutics), Octagam (Octapharma), Panzyga (Pfizer), Privigen (CSL Behring), and Yimmugo (Biotest AG).<sup>3</sup>

Several subcutaneous immunoglobulin products have been approved by the FDA. They include Cutaquig (Octapharma), Cuvitru (Takeda), Gammagard Liquid (Takeda), Gammaked (Kedrion Biopharma), Gamunex-C (Grifols Therapeutics), Hizentra CSL (Behring AG), Hyqvia (Takeda), and Xembify (Grifols Therapeutics).<sup>3</sup>

At least one IVIG product is FDA-approved to treat the following conditions<sup>3</sup>:

- Primary humoral immunodeficiency
- Multifocal motor neuropathy
- B-cell chronic lymphocytic leukemia
- Immune (aka idiopathic) thrombocytopenic purpura



- Kawasaki syndrome
- Dermatomyositis
- Chronic inflammatory demyelinating polyneuropathy (CIDP)

## References

1. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. *Neurology*. May 1991; 41(5): 617-8. PMID 2027473
2. Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. *Eur J Neurol*. 2010;17:356-363. doi: 10.1111/j.1468-1331.2009.02930.x. <https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1468-1331.2009.02930.x>. Resource archived.
3. Food and Drug Administration (FDA). Vaccines, Blood & Biologics: Immune Globulins. 2020; <https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immune-globulins>. Accessed Resource archived .
4. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. *Transfus Med Rev*. Jan 2010; 24 Suppl 1: S28-50. PMID 19962579
5. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. *J Clin Immunol*. May 2006; 26(3): 265-73. PMID 16783465
6. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. *J Clin Immunol*. Mar 2006; 26(2): 177-85. PMID 16758340
7. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. *Drugs*. Aug 2013; 73(12): 1307-19. PMID 23861187
8. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. *J Clin Oncol*. Feb 10 2009; 27(5): 770-81. PMID 19114702
9. Bourassa-Blanchette S, Knoll GA, Hutton B, et al. Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis. *Clin Transplant*. Jun 2019; 33(6): e13560. PMID 30938866
10. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. *J Am Soc Nephrol*. Dec 2004; 15(12): 3256-62. PMID 15579530
11. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. *N Engl J Med*. Jul 17 2008; 359(3): 242-51. PMID 18635429
12. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. *Transplantation*. Jul 27 2012; 94(2): 165-71. PMID 22735712
13. Kozlowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time?. *Ann Transplant*. Apr-Jun 2011; 16(2): 19-25. PMID 21716181
14. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. *Transplantation*. Aug 27 2012; 94(4): 345-51. PMID 22820699



15. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. *Am J Transplant*. Feb 2006; 6(2): 346-51. PMID 16426319
16. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. *J Am Soc Nephrol*. Dec 2012; 23(12): 2061-71. PMID 23160511
17. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. *N Engl J Med*. Jul 28 2011; 365(4): 318-26. PMID 21793744
18. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. *Transplantation*. Oct 27 2012; 94(8): 775-83. PMID 23032865
19. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. *Transplantation*. Jan 15 2001; 71(1): 53-8. PMID 11211195
20. Gale RP, Chapel HM, Bunch C, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. *N Engl J Med*. Oct 06 1988; 319(14): 902-7. PMID 2901668
21. Boughton BJ, Jackson N, Lim S, et al. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. *Clin Lab Haematol*. Mar 1995; 17(1): 75-80. PMID 7621634
22. Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. *Haematologica*. Mar-Apr 1996; 81(2): 121-6. PMID 8641639
23. Chapel H, Dicato M, Gamm H, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. *Br J Haematol*. Sep 1994; 88(1): 209-12. PMID 7803248
24. Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. *Blood*. Feb 1989; 73(2): 366-8. PMID 2492832
25. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. *Leuk Lymphoma*. May 2009; 50(5): 764-72. PMID 19330654
26. National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. *N Engl J Med*. Jul 11 1991; 325(2): 73-80. PMID 1675763
27. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. *Cochrane Database Syst Rev*. Jul 02 2013; (7): CD000361. PMID 23821390
28. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. *Cochrane Database Syst Rev*. Jan 29 2020; 1: CD001239. PMID 31995649
29. Brocklehurst P, Farrell B, King A, et al. Treatment of neonatal sepsis with intravenous immune globulin. *N Engl J Med*. Sep 29 2011; 365(13): 1201-11. PMID 21962214
30. Busani S, Damiani E, Cavazzuti I, et al. Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. *Minerva Anestesiol*. May 2016; 82(5): 559-72. PMID 26474267
31. Ito S, Oyake T, Uchiyama T, et al. Successful treatment with cyclosporine and high-dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia. *Int J Hematol*. Oct 2004; 80(3): 250-3. PMID 15540900
32. Koduri PR, Kumapley R, Khokha ND, et al. Red cell aplasia caused by parvovirus B19 in AIDS: use of i.v. immunoglobulin. *Ann Hematol*. Jul-Aug 1997; 75(1-2): 67-8. PMID 9322687
33. Chuhjo T, Nakao S, Matsuda T. Successful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with low-dose immunoglobulin. *Am J Hematol*. Mar 1999; 60(3): 222-4. PMID 10072114



34. Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. *Clin Infect Dis.* Apr 2013; 56(7): 968-77. PMID 23243178
35. Darenberg J, Ihendyane N, Sjolín J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. *Clin Infect Dis.* Aug 01 2003; 37(3): 333-40. PMID 12884156
36. Linner A, Darenberg J, Sjolín J, et al. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. *Clin Infect Dis.* Sep 15 2014; 59(6): 851-7. PMID 24928291
37. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. *Clin Infect Dis.* Apr 1999; 28(4): 800-7. PMID 10825042
38. Norrby-Teglund A, Muller MP, McGeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. *Scand J Infect Dis.* 2005; 37(3): 166-72. PMID 15849047
39. Shah SS, Hall M, Srivastava R, et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. *Clin Infect Dis.* Nov 01 2009; 49(9): 1369-76. PMID 19788359
40. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. *Transfus Med Rev.* Apr 2007; 21(2 Suppl 1): S9-56. PMID 17397769
41. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. *Lancet.* Jan 05 2002; 359(9300): 23-9. PMID 11809183
42. von dem Borne AE, Vos JJ, Pegels JG, et al. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. *Br Med J (Clin Res Ed).* Jan 23 1988; 296(6617): 249-50. PMID 2449258
43. Jacobs P, Wood L. The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia. An interim analysis. *Blut.* Jul 1989; 59(1): 92-5. PMID 2752179
44. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. *Cochrane Database Syst Rev.* Sep 19 2014; (9): CD002063. PMID 25238327
45. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. *Lancet.* Jan 25 1997; 349(9047): 225-30. PMID 9014908
46. Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. *Cochrane Database Syst Rev.* Jan 24 2007; (1): CD004761. PMID 17253522
47. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. *Cochrane Database Syst Rev.* 2003; (4): CD004000. PMID 14584002
48. Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. *Cochrane Database Syst Rev.* Jan 31 2013; (1): CD007057. PMID 23440811
49. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. *QJM.* Jul 2000; 93(7): 433-9. PMID 10874052
50. Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. *Cochrane Database Syst Rev.* Dec 30 2013; (12): CD001797. PMID 24379104
51. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. *Ann Neurol.* Dec 1994; 36(6): 838-45. PMID 7998769
52. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. *Ann Neurol.* Aug 2001; 50(2): 195-201. PMID 11506402



53. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. *Lancet Neurol.* Jun 2012; 11(6): 493-502. PMID 22578914
54. Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. *J Neurol Neurosurg Psychiatry.* Jan 1993; 56(1): 36-9. PMID 8429321
55. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. *Brain.* Aug 1996; 119 ( Pt 4): 1067-77. PMID 8813271
56. Thompson N, Choudhary P, Hughes RA, et al. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. *J Neurol.* Mar 1996; 243(3): 280-5. PMID 8936360
57. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. *Neurology.* Feb 27 2001; 56(4): 445-9. PMID 11222785
58. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. *Lancet Neurol.* Feb 2008; 7(2): 136-44. PMID 18178525
59. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol.* Jan 2018; 17(1): 35-46. PMID 29122523
60. Markvardsen LH, Sindrup SH, Christiansen I, et al. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. *Eur J Neurol.* Feb 2017; 24(2): 412-418. PMID 28000311
61. van Schaik IN, van den Berg LH, de Haan R, et al. Intravenous immunoglobulin for multifocal motor neuropathy. *Cochrane Database Syst Rev.* Apr 18 2005; (2): CD004429. PMID 15846714
62. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. *Neurology.* Mar 1994; 44(3 Pt 1): 429-32. PMID 8145910
63. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. *Neurology.* Nov 14 2000; 55(9): 1256-62. PMID 11087764
64. Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. *Brain.* Jan 2001; 124(Pt 1): 145-53. PMID 11133794
65. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. *J Neurol Neurosurg Psychiatry.* Sep 1995; 59(3): 248-52. PMID 7673950
66. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. *Neurology.* Sep 1996; 47(3): 678-83. PMID 8797464
67. Muchnik S, Losavio AS, Vidal A, et al. Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. *Muscle Nerve.* Jun 1997; 20(6): 674-8. PMID 9149073
68. Rich MM, Teener JW, Bird SJ. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. *Muscle Nerve.* May 1997; 20(5): 614-5. PMID 9140371
69. Takano H, Tanaka M, Koike R, et al. Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. *Muscle Nerve.* Sep 1994; 17(9): 1073-5. PMID 8065398
70. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. *Neurology.* Jul 1992; 42(7): 1422-3. PMID 1620360



71. Elson L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. *Mult Scler.* Apr 2014; 20(4): 501-4. PMID 23986097
72. Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. *Neurologia.* Mar 2013; 28(2): 65-72. PMID 22841880
73. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. *Cochrane Database Syst Rev.* Dec 12 2012; 12: CD002277. PMID 23235588
74. Zinman L, Ng E, Brill V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. *Neurology.* Mar 13 2007; 68(11): 837-41. PMID 17353471
75. Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. *Neurology.* Jun 07 2011; 76(23): 2017-23. PMID 21562253
76. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. *Arch Neurol.* Nov 2005; 62(11): 1689-93. PMID 16286541
77. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. *Ann Neurol.* Jun 1997; 41(6): 789-96. PMID 9189040
78. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology.* Jan 22 2002; 58(2): 169-78. PMID 11805241
79. Gurcan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. *Am J Clin Dermatol.* 2010; 11(5): 315-26. PMID 20642294
80. Amagai M, Ikeda S, Hashimoto T, et al. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. *J Dermatol Sci.* Feb 2017; 85(2): 77-84. PMID 27876358
81. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. *J Am Acad Dermatol.* Apr 2009; 60(4): 595-603. PMID 19293008
82. Huang YC, Chien YN, Chen YT, et al. Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. *G Ital Dermatol Venereol.* Oct 2016; 151(5): 515-24. PMID 27248150
83. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. *Int J Dermatol.* Jan 2015; 54(1): 108-15. PMID 24697283
84. Wang DX, Shu XM, Tian XL, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. *Clin Rheumatol.* May 2012; 31(5): 801-6. PMID 22274797
85. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. *N Engl J Med.* Dec 30 1993; 329(27): 1993-2000. PMID 8247075
86. Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. *Mod Rheumatol.* Jun 2012; 22(3): 382-93. PMID 21971943
87. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. *Neurology.* Mar 1997; 48(3): 712-6. PMID 9065553
88. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. *J Neurol.* Jan 2000; 247(1): 22-8. PMID 10701893
89. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. *Neurology.* Feb 13 2001; 56(3): 323-7. PMID 11171896
90. Sakthiswary R, D'Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis. *Medicine (Baltimore).* Oct 2014; 93(16): e86. PMID 25310743



91. Boletis JN, Ioannidis JP, Boki KA, et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. *Lancet*. Aug 14 1999; 354(9178): 569-70. PMID 10470708
92. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. *J Allergy Clin Immunol*. Apr 2006; 117(4 Suppl): S525-53. PMID 16580469
93. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. *Neurology*. Mar 08 2005; 64(5): 804-10. PMID 15753413
94. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. *Neurology*. Jun 12 2001; 56(11): 1514-22. PMID 11402108
95. Rogosnitzky M, Danks R, Holt D. Intravenous immunoglobulin for the treatment of Crohn's disease. *Autoimmun Rev*. Dec 2012; 12(2): 275-80. PMID 22579561
96. Rajagopala S, Singh N. Diagnosing and treating hemophagocytic lymphohistiocytosis in the tropics: systematic review from the Indian subcontinent. *Acta Med Acad*. 2012; 41(2): 161-74. PMID 23331391
97. Hot A, Madoux MH, Viard JP, et al. Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins. *Am J Hematol*. Feb 2008; 83(2): 159-62. PMID 17849465
98. Ostronoff M, Ostronoff F, Coutinho M, et al. Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma; successful treatment with high-dose intravenous immunoglobulin. *Bone Marrow Transplant*. Apr 2006; 37(8): 797-8. PMID 16518425
99. Arlet JB, Le TH, Marinho A, et al. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. *Ann Rheum Dis*. Dec 2006; 65(12): 1596-601. PMID 16540551
100. Flores G, Cunningham-Rundles C, Newland AC, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. *Am J Hematol*. Dec 1993; 44(4): 237-42. PMID 8237993
101. Macintyre EA, Linch DC, Macey MG, et al. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. *Br J Haematol*. Jun 1985; 60(2): 387-8. PMID 4005186
102. Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. *Arthritis Rheum*. Aug 2006; 54(8): 2568-76. PMID 16868979
103. Rayment R, Brunskill SJ, Soothill PW, et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. *Cochrane Database Syst Rev*. May 11 2011; (5): CD004226. PMID 21563140
104. Paridaans NP, Kamphuis MM, Taune Wikman A, et al. Low-Dose versus Standard-Dose Intravenous Immunoglobulin to Prevent Fetal Intracranial Hemorrhage in Fetal and Neonatal Alloimmune Thrombocytopenia: A Randomized Trial. *Fetal Diagn Ther*. 2015; 38(2): 147-53. PMID 25896635
105. Berkowitz RL, Lesser ML, McFarland JG, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. *Obstet Gynecol*. Aug 2007; 110(2 Pt 1): 249-55. PMID 17666597
106. Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. *Obstet Gynecol*. Jan 2006; 107(1): 91-6. PMID 16394045
107. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. *Am J Obstet Gynecol*. May 1996; 174(5): 1414-23. PMID 9065105
108. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. *Cochrane Database Syst Rev*. Apr 19 2006; (2): CD000112. PMID 16625529
109. Egerup P, Lindschou J, Gluud C, et al. The Effects of Intravenous Immunoglobulins in Women with Recurrent Miscarriages: A Systematic Review of Randomised Trials with Meta-Analyses and Trial Sequential Analyses Including Individual Patient Data. *PLoS One*. 2015; 10(10): e0141588. PMID 26517123





110. Wang SW, Zhong SY, Lou LJ, et al. The effect of intravenous immunoglobulin passive immunotherapy on unexplained recurrent spontaneous abortion: a meta-analysis. *Reprod Biomed Online*. Dec 2016; 33(6): 720-736. PMID 27720163
111. Christiansen OB, Pedersen B, Rosgaard A, et al. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. *Hum Reprod*. Mar 2002; 17(3): 809-16. PMID 11870141
112. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. *Am J Obstet Gynecol*. Jan 2000; 182(1 Pt 1): 122-7. PMID 10649166
113. Jablonowska B, Selbing A, Palfi M, et al. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. *Hum Reprod*. Mar 1999; 14(3): 838-41. PMID 10221723
114. Williams KA, Swedo SE, Farmer CA, et al. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. *J Am Acad Child Adolesc Psychiatry*. Oct 2016; 55(10): 860-867.e2. PMID 27663941
115. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. *Lancet*. Oct 02 1999; 354(9185): 1153-8. PMID 10513708
116. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. *J Autism Dev Disord*. Aug 1996; 26(4): 439-52. PMID 8863094
117. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. *J Child Neurol*. Feb 1998; 13(2): 79-82. PMID 9512308
118. DelGiudice-Asch G, Simon L, Schmeidler J, et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. *J Autism Dev Disord*. Apr 1999; 29(2): 157-60. PMID 10382136
119. Goebel A, Bisla J, Carganillo R, et al. Low-Dose Intravenous Immunoglobulin Treatment for Long-Standing Complex Regional Pain Syndrome: A Randomized Trial. *Ann Intern Med*. Oct 03 2017; 167(7): 476-483. PMID 28973211
120. Goebel A, Baranowski A, Maurer K, et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. *Ann Intern Med*. Feb 02 2010; 152(3): 152-8. PMID 20124231
121. Relkin NR, Thomas RG, Rissman RA, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. *Neurology*. May 02 2017; 88(18): 1768-1775. PMID 28381506
122. Kile S, Au W, Parise C, et al. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. *J Neurol Neurosurg Psychiatry*. Feb 2017; 88(2): 106-112. PMID 26420886
123. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. *Lancet Neurol*. Mar 2013; 12(3): 233-43. PMID 23375965
124. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. *J Neurol*. Oct 2002; 249(10): 1370-7. PMID 12382151
125. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. *Ann Neurol*. Nov 1996; 40(5): 792-5. PMID 8957021
126. Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. *Am J Med*. Jul 1997; 103(1): 38-43. PMID 9236484
127. Robinson J, Hartling L, Vandermeer B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. *Cochrane Database Syst Rev*. May 20 2015; (5): CD004370. PMID 25992494
128. Robinson J, Hartling L, Vandermeer B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. *Cochrane Database Syst Rev*. Aug 19 2020; 8: CD004370. PMID 32835416



129. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. *Circulation*. May 08 2001; 103(18): 2254-9. PMID 11342473
130. Kishimoto C, Shioji K, Hashimoto T, et al. Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance. *Heart Vessels*. May 2014; 29(3): 336-42. PMID 23702697
131. El-Saiedi SA. Randomized controlled trial on the use of intravenous immune globulin in acute pediatric myocarditis. *J Clin Res Bioethics*. 2013;5(1):1-5. <https://www.longdom.org/open-access/randomized-controlled-trial-on-the-use-of-intravenous-immune-globulin-2155-9627-5-170.pdf>. Accessed August 27, 2024.
132. Huang X, Sun Y, Su G, et al. Intravenous Immunoglobulin Therapy for Acute Myocarditis in Children and Adults. *Int Heart J*. Mar 20 2019; 60(2): 359-365. PMID 30745539
133. Heidendael JF, Den Boer SL, Wildenbeest JG, et al. Intravenous immunoglobulins in children with new onset dilated cardiomyopathy. *Cardiol Young*. Jan 2018; 28(1): 46-54. PMID 28797313
134. Imazio M, Lazaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. *J Cardiovasc Med (Hagerstown)*. Apr 2016; 17(4): 263-9. PMID 26090917
135. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. *N Engl J Med*. Dec 27 2001; 345(26): 1870-6. PMID 11756577
136. LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. *Ocul Immunol Inflamm*. Mar 2000; 8(1): 49-57. PMID 10806434
137. Rosenbaum JT, George RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. *Am J Ophthalmol*. May 1999; 127(5): 545-9. PMID 10334347
138. Huang YH, Chen HC, Huang KW, et al. Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis. *BMC Neurol*. Mar 22 2015; 15: 39. PMID 25886512
139. Madsen MB, Hjortrup PB, Hansen MB, et al. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. *Intensive Care Med*. Nov 2017; 43(11): 1585-1593. PMID 28421246
140. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. *J Allergy Clin Immunol*. Mar 2017; 139(3S): S1-S46. PMID 28041678
141. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol*. Nov 2015; 136(5): 1186-205.e1-78. PMID 26371839
142. Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. *Transfus Med Rev*. Jan 2010; 24 Suppl 1: S7-S27. PMID 19962580
143. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 4.2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/cll.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf). Resource archived.
144. Centers for Disease Control (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: bacterial infections. 2013.
145. Polin RA, Committee on Fetus Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. *Pediatrics*.
146. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. Mar 27 2012; 78(13): 1009-15. PMID 22454268
147. Saguil A, Fargo M, Grogan S. Diagnosis and management of kawasaki disease. *Am Fam Physician*. Mar 15 2015; 91(6): 365-71. PMID 25822554



148. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*. Apr 25 2017; 135(17): e927-e999. PMID 28356445
149. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. *J Peripher Nerv Syst*. 2021;1-27. <https://onlinelibrary.wiley.com/doi/10.1111/jns.12455>. Accessed August 27, 2024.
150. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). *J Neurol*. Jan 2014; 261(1): 1-16. PMID 24272588
151. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. Jul 26 2016; 87(4): 419-25. PMID 27358333
152. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. *Arch Dermatol*. Aug 2003; 139(8): 1051-9. PMID 12925395
153. Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. *Br J Dermatol*. Jun 2016; 174(6): 1194-227. PMID 27317286
154. McPherson T, Exton LS, Biswas S, et al. British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. *Br J Dermatol*. 2019;181:37-54. doi: 10.1111/bjd.17841. <https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjd.17841>. Accessed August 27, 2024.
155. Cervera R, Rodriguez-Pinto I, Cervera R, et al. Catastrophic antiphospholipid syndrome: task force report summary. *Lupus*. Oct 2014; 23(12): 1283-5. PMID 25228727
156. Royal College of Obstetricians and Gynecologists. The Investigation and Treatment of Couples with Recurrent Firsttrimester and Second-trimester Miscarriage. Royal College of Obstetricians and Gynecologists Green-Top Guidelines No. 17. 2011; [https://www.rcog.org.uk/globalassets/documents/guidelines/gtg\\_17.pdf](https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf). Accessed August 27, 2024.
157. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. *Transfus Med Rev*. Apr 2007; 21(2 Suppl 1): S57-107. PMID 17397768
158. Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*. Feb 2014; 53(2): 237-57. PMID 24472258
159. National Institute for Health and Care Excellence (NICE). Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management [CG53]. 2007; <https://www.nice.org.uk/guidance/cg53>. Accessed August 27, 2024.
160. Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. [https://www.jacc.org/doi/full/10.1016/j.jacc.2013.05.019?\\_ga=2.248107975.1773510622.1630531729-1275499959.1630531729](https://www.jacc.org/doi/full/10.1016/j.jacc.2013.05.019?_ga=2.248107975.1773510622.1630531729-1275499959.1630531729). Accessed August 27, 2024.
161. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for intravenous immune globulin for the treatment of autoimmune mucocutaneous blistering diseases (250.3). 2002; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=158>. Accessed August 27, 2024.

## History



Date	Comments
09/01/98	Add to Therapy Section - New Policy
03/22/99	Replace Policy - Added myasthenia gravis to medically necessary indications
02/12/02	Replace Policy - Updated policy approved by P&T committee January 2002. No change to policy statement, added reference.
02/11/03	Replace Policy - Updated policy approved by P&T committee February 2003. No change to policy statement.
07/08/03	Replace Policy - Policy replaces CP.MP.PR.8.01.103. Policy updated; added 2 medically necessary myasthenia gravis indications and additional information in the rationale section on autoimmune mucocutaneous blistering diseases, stiff person syndrome, organ transplant rejection, non-infectious uveitis, and demyelinating optic neuritis.
05/11/04	Replace Policy - Policy replaces CP.MP.BC.8.01.05. Policy reviewed and updated by P&T committee 3/24/04; policy statements concerning medically necessary and investigational conditions significantly revised. Policy guidelines, rationale, and references updated.
09/01/04	Replace Policy - Policy renumbered from PR.8.01.103. No changes to dates.
05/10/05	Replace Policy - Scheduled review; policy reviewed and approved by P&T 3/22/05; policy statement changed to remove autoimmune hemolytic anemia from investigational and add B-cell malignancy as medically necessary.
04/11/06	Replace Policy - Scheduled review; minor clarification changes to the policy statement; policy reviewed and approved by P&T 3/28/06.
06/02/06	Disclaimer and Scope update - No other changes.
12/21/06	Codes Updated - No other changes.
05/08/07	Replace Policy - Policy updated with literature review; references added. Policy statement updated to include pure red cell aplasia as a medically necessary off-label indication for IVIg. Reviewed by P&T on March 27, 2007.
08/23/07	Codes Updated - No other changes.
03/11/08	Cross Reference Updated - No other changes.
05/13/08	Replace Policy - Policy updated with literature search; no change to the policy statement. Reviewed by P&T committee on March 25, 2008. Code Q4097 added.
01/13/09	Code Updates - Code added, J1459; effective 1/1/09.
06/09/09	Replace Policy - Policy updated with literature search. Policy updated to include b cell diagnosis under the medically necessary statement. Reviewed by P&T committee March 2009.
03/09/10	Replace Policy - Policy updated with literature search. Multiple Myeloma deleted from the Investigational criteria list in the policy statement. Reviewed by Pharmacy in January 2010.



Date	Comments
08/10/10	Replace Policy - Policy updated to include treatment of antibody-mediated rejection or high risk of antibody-mediated rejection of solid organ transplants is considered medically necessary. Codes added: 90284, 96365, 96366, 96369, 96370, 96371; J1567, J1572.
05/10/11	Replace Policy - PANDAS added to the list of investigational applications within the Policy section; Rationale updated in support of this addition. References added.
07/12/11	Replace Policy - Policy updated policy statements for Hizentra: considered medically necessary for FDA-approved indication for txt of PIDD; considered medically necessary for subcutaneous administration as equal to any other IVIG drug as listed as medically necessary in this policy; and considered investigational for any other indication. Description and Rationale sections updated; reference added. Reviewed by P&T in May 2011. Title changed; "Intravenous" removed, to leave the title as "Immune Globulin Therapy".
01/27/12	Codes updated; HCPCS codes J1557 and J7183 added.
02/21/12	Code update; HCPCS code J1559 added to the policy.
04/10/12	Replace policy. Policy rewritten and reorganized, merging content from 8.01.05 (not an active policy). Policy Guidelines updated to support new policy statements. Reviewed by P&T on March 27, 2012. Codes added: J1599 and 90284; code J1567 removed. This policy was approved with a 90-day hold for provider notification and is effective September 1, 2012.
11/26/12	Update Related Policies. Add 5.01.526.
12/09/13	Replace policy. Policy updated with literature search through February 12, 2013. Clinical input added. References 30, 44, 83-86, 97 and 98 added; other references renumbered or removed. PANDAs moved to investigational from medically necessary; birdshot retinopathy added as investigational; laboratory testing section removed from policy. Rationale updated.
03/10/14	Annual Review. Organ transplant rejection deleted from investigational list because it has been considered medically necessary since 2010.
08/11/15	Interim Review. Policy tabled at August MPC meeting for further revisions and formatting changes.
09/08/15	Annual Review. Diagnoses added to Medically Necessary statement: Hemolytic disease of the fetus and newborn (aka erythroblastosis fetalis), Stevens-Johnson syndrome, toxic epidermal necrolysis. Clarified B-Cell-like pathology indications under hematologic subheading. Postpolio syndrome added to Investigational policy statement. Policy statement for treatment of relapsing/remitting multiple sclerosis changed from medically necessary to <u>not</u> medically necessary. Diagnostic criteria for CIDP and MMN moved from the Appendix to the Policy Guidelines section. Subheading for Initial and Ongoing Authorization of Coverage added to Policy Guidelines. All lists are put in alphabetical order. Policy updated with literature review through April 20, 2015. References 26, 27, 53, 73-74, 80, 91 added. Policy statements



Date	Comments
	revised as noted. Removed CPT codes 96360, 96361, 96365, 96366, 96399, 95370, 96371; all PX/DX ICD9/ICD10 codes; and HCPCS code J7183 – these are not reviewed in relationship to this policy.
12/11/15	Interim update. Minor formatting change to Policy Guidelines for clarity.
01/20/16	Coding update. New HCPCS code J1575, effective 1/1/16, added to policy.
01/27/16	Minor edit. Reordered codes in coding table for numeric order.
02/01/16	Coding update. HCPCS code J1556 added to policy.
05/01/16	Annual Review, approved April 12, 2016. Policy updated with criteria for site of service for IV infusion of IVIG – considered medically necessary in hospital-based outpatient center only when criteria are met. Policy section reformatted for purposes of clarity and understandability.
05/17/16	Minor edit. Corrected typo related to INCAT sensory sum score.
07/01/16	Interim Review, approved June 14, 2016. Correction made to site of service administration criteria.
10/01/16	Interim update, approved September 13, 2016. Coding updated. Policy moved into new policy format.
11/01/16	Interim Review, approved October 11, 2016. Clarified age criteria language indicating that site of service review is applicable to only those age 13 and older; drug criteria review applies to all ages.
02/01/17	Annual Review, approved January 10, 2017. Content adopted from BCBSA most recent update, with literature review through October 2016. New covered indications include stiff-person syndrome, polymyositis, and Wegener’s granulomatosis, patients with CLL who meet criteria, and neuromyelitis optica. The following were changed from medically necessary to investigational: treatment of antibody mediated rejection following solid organ transplantation, patients with neonatal sepsis (prophylaxis or treatment), patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Coding update; removed 90281, 96365, 96366, 96369, 96370 and 96371.
04/01/17	Interim Review, approved March 14, 2017. Five indications, intended for inclusion in the January 2017 update, were unintentionally omitted. These 5 indications: toxic shock syndrome (references 36-39 added), warm antibody autoimmune hemolytic anemia (reference 106 and 107 added), antiphospholipid syndrome (references 108 added), X-linked hyper-IgM syndrome, and ataxia telangiectasia. Section on dosing related to rituximab was deleted because it was a typographical error.
07/01/17	Formatting update; added hyperlinks to Medical Necessity sections.
09/12/17	Formatting updated for clarity in Policy Guidelines section.
11/01/17	Interim Review, approved October 10, 2017. Policy updated to address different therapy approach for ITP for Pediatrics versus Adults based on specialty input. Additional detail for alternative treatments added to policy. Clarified site of service



Date	Comments
	exception criterion related to access: There is no outpatient infusion center within 50 miles of the patient's home and there is no contracted home infusion agency that will travel to their home, or a hospital is the only place that offers infusions of this drug.
01/01/18	Coding update; added HCPCS code J1555 (new code effective 1/1/18).
02/14/18	Interim Review, approved February 13, 2018. Update hospital-based outpatient coverage from 30 days to 90 days.
02/20/18	Coding update; removed HCPCS code J1460.
05/01/18	Annual Review, approved April 18, 2018. Clarified initial and ongoing authorization criteria. Policy updated with literature search. Medically necessary statement for neuromyelitis optica changed to state when there is contraindication to, or lack of response to, "first-line treatment (particularly in children)". Removed references 95, 96, 122, and 159 as well as duplicate references. Added references 84, 118, 126, and 138. Policy statements otherwise unchanged.
06/01/18	Minor update. Removed IVIG bullet from adult ITP criteria that had been added incorrectly from a related pharmacy policy.
07/01/18	Interim Review, approved June 22, 2018. Reference 155 added. Policy statement updated to read "IVIG therapy is considered not medically necessary for patients with any type of multiple sclerosis." The words relapsing remitting were removed.
11/01/18	Minor update, the Site of Service criteria was updated for clarity.
01/01/19	Interim Review, approved December 13, 2018. References 156, 157 added. Medically necessary indications added for those undergoing/undergone CAR-T cell therapy and for specific antibody deficiency (SAD) and ITP in an adult with a platelet count less than 10,000/mm <sup>3</sup> . Additional edit approved December 19, 2018. Multiple myeloma is considered investigational; this was inadvertently not reflected in previous policy history.
01/01/20	Annual Review, approved December 10, 2019. Policy updated with literature search through August 2019; references added. Policy statements unchanged. Added Cuvitru and Hyqvia to policy.
07/01/20	Coding update. Added code J1558.
01/01/21	Annual Review, approved December 8, 2020. Policy updated with literature search through August 24, 2020; references added. The following were changed from medically necessary to investigational: IVIG for prophylactic use post HCT, CLL, lymphoma, multiple myeloma or solid organ transplant, and prior to solid organ transplant, treatment for patients at high risk of antibody-mediated rejection including highly sensitized patients and those receiving an ABO-compatible organ. Also, some first-line treatments have been updated and other minor edits made for clarity. Removed HCPCS code J1562. Added HCPCS code C9072. Policy changes effective for dates of service on or after April 7, 2021, following provider notification.



Date	Comments
04/07/21	Coding update. Added HCPC code J1554 and added term date 4/1/2021 to HCPC C9072.
11/01/21	Annual Review, approved October 21, 2021. Policy update with literature search through August 31, 2021; references added. Policy statements unchanged. Added site of service review for Asceniv (immune globulin intravenous, human – slra) for dates of service on or after February 4, 2022. Added HCPCS code J3590.
07/01/22	Coding update. Added HCPCS code J1551. Removed HCPCS codes C9072 and J3590.
08/01/22	Annual Review, approved July 12, 2022. Added site of service review for Cutaquig (immune globulin) for dates of service on or after November 4, 2022.
04/01/23	Annual Review, approved March 14, 2023. Added treatment for encephalitis as investigational. Added medical necessity coverage for acute antibody-mediated transplant rejection. Changed the wording from "patient" to "individual" throughout the policy for standardization.
07/01/23	Coding update. Added new HCPCS code J1576.
02/01/24	Annual Review, approved January 9, 2024. Added site of service review for Panzyga (immune globulin). Removed HCPCS code J1566 for Carimune as it has been removed from the market.
03/01/24	Coding update. Added HCPCS code J1566 back to the policy.
08/01/24	Interim Review, approved July 9, 2024. Clarified IVIG coverage criteria for Guillain-Barré syndrome. Updated IVIG coverage criteria to include treatment of certain individuals with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Updated IgG level requirements from <400 mg/dL to <500 mg/dL across the initial criteria in the policy. Added re-authorization requirement to have an IgG ≥300 mg/dL.
09/01/24	Interim Review, approved August 26, 2024. The following policy change is effective December 5, 2024, following 90-day provider notification. Added site of service review for Alyglo (immune globulin intravenous, human-stwk).
12/01/24	Interim Review, approved November 12, 2024. Added Yimmugo (immune globulin intravenous, human-dira) to the policy. Added treatment for certain individuals in a humoral immunodeficiency state with acute lymphocytic leukemia (ALL). Removed the requirement to have recurrent or persistent infections from the humoral immunodeficiency states coverage criteria. Added HCPCS code J3590 to report Yimmugo.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply.





CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2024 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

